var title_f40_42_41632="Pericardial effusion due to hypothyroidism";
var content_f40_42_41632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion due to hypothyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large pericardial effusion in a severely hypothyroid woman with no underlying heart disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Neha Malhotra.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41632=[""].join("\n");
var outline_f40_42_41632=null;
var title_f40_42_41633="HSG hydrosalpinx";
var content_f40_42_41633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 535px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Hysterosalpingogram (HSG) showing a normal uterine cavity with filling,but no definite spillage from the tubes. (B) Hysterosalpingogram of the same patient shown in A after more dye was injected, now bilateral hydrosalpinx can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41633=[""].join("\n");
var outline_f40_42_41633=null;
var title_f40_42_41634="Bamboo spine in AS";
var content_f40_42_41634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F75935%7ERHEUM%2F50665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F75935%7ERHEUM%2F50665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bamboo spine in AS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radiograph of the lumbar sacral spine in a patient with advanced ankylosing spondylitis showing a \"bamboo spine\" with vertebral fusion (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusion of sacroiliac joints in AS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ankylosis of the sacroiliac joint in advanced ankylosing spondylitis with complete obliteration of the joint space.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41634=[""].join("\n");
var outline_f40_42_41634=null;
var title_f40_42_41635="Latanoprost: Drug information";
var content_f40_42_41635=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Latanoprost: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/22/22884?source=see_link\">",
"    see \"Latanoprost: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xalatan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Latanoprost&reg;;",
"     </li>",
"     <li>",
"      CO Latanoprost;",
"     </li>",
"     <li>",
"      GD-Latanoprost;",
"     </li>",
"     <li>",
"      Xalatan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F187090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Prostaglandin, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F187064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Glaucoma:",
"     </b>",
"     Ophthalmic: 1 drop (1.5 mcg) in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP lowering effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     A medication delivery device (Xal-Ease&trade;) is available for use with Xalatan&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F187065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16160272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16160273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.005% (2.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xalatan&reg;: 0.005% (2.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F187046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. A delivery aid, Xal-Ease&trade;, is available for administering Xalatan&reg;.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F187044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Latanoprost may be confused with Lantus&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Xalatan&reg; may be confused with Lantus&reg;, Travatan&reg;, Xalacom&trade;, Zarontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F187088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;5% to 15%: Ocular: Blurred vision, burning and stinging, conjunctival hyperemia, foreign body sensation, itching, increased pigmentation of the iris, punctate epithelial keratopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina pectoris (1% to 2%), chest pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Allergic skin reaction (1% to 2%), rash (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1% to 2%), back pain (1% to 2%), myalgia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Dry eye (1% to 4%), excessive tearing (1% to 4%), eye pain (1% to 4%), lid crusting (1% to 4%), lid edema (1% to 4%), lid erythema (1% to 4%), lid discomfort/pain (1% to 4%), photophobia (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cold (4%), upper respiratory tract infection (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Asthma, herpes keratitis, iritis, keratitis, retinal artery embolus, retinal detachment, toxic epidermal necrolysis, uveitis, vitreous hemorrhage from diabetic retinopathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F187049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to latanoprost, benzalkonium chloride, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F187033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure-, inflammatory-, or neovascular glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F187038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bimatoprost: The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Ophthalmic): May diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13376205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies at maternally toxic doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12990146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F187051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Latanoprost Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (2.5 mL): $95.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xalatan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.005% (2.5 mL): $131.11",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F187052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      9 PM eye drops (IN);",
"     </li>",
"     <li>",
"      Gaap Ofteno (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Glautan (IL);",
"     </li>",
"     <li>",
"      Lanoprost (TW);",
"     </li>",
"     <li>",
"      Lanotan (KP);",
"     </li>",
"     <li>",
"      Latanox (CO);",
"     </li>",
"     <li>",
"      Lataro (KP);",
"     </li>",
"     <li>",
"      Latipress (PH);",
"     </li>",
"     <li>",
"      Louten (AR, CN, PY, UY);",
"     </li>",
"     <li>",
"      Protan (KP);",
"     </li>",
"     <li>",
"      Xalatan (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, HK, HU, ID, IE, IL, IN, IQ, IR, IT, JO, KP, KW, LB, LY, MX, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, QA, RU, SA, SE, SG, SY, TH, TR, TW, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Zakol (PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F187032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Latanoprost is a prostaglandin F",
"     <sub>",
"      2",
"     </sub>",
"     -alpha analog believed to reduce intraocular pressure by increasing the outflow of the aqueous humor",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F187048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Maximum: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Through the cornea where the isopropyl ester prodrug is hydrolyzed by esterases to the biologically active acid. Peak concentration is reached in 2 hours after topical administration in the aqueous humor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.16 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via fatty acid beta-oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 17 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Patel SS and Spencer CM, &ldquo;Latanoprost: A Review of Its Pharmacological Properties, Clinical Efficacy and Tolerability in the Management of Primary Open-Angle Glaucoma and Ocular Hypertension,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1996, 9(5):363-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/42/41635/abstract-text/8922563/pubmed\" id=\"8922563\" target=\"_blank\">",
"        8922563",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9547 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41635=[""].join("\n");
var outline_f40_42_41635=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187090\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187064\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187065\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160272\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16160273\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187043\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187029\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187046\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187044\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187095\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187088\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187049\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187033\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299578\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187038\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187040\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376205\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12990146\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187051\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187052\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187032\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187048\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9547|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/22/22884?source=related_link\">",
"      Latanoprost: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41636="Belladonna and opium: Pediatric drug information";
var content_f40_42_41636=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Belladonna and opium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?25/41/26261?source=see_link\">",
"    see \"Belladonna and opium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/35/12852?source=see_link\">",
"    see \"Belladonna and opium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Urinary",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1000009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/41/26261?source=see_link\">",
"      see \"Belladonna and opium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rectal: Adults: 1 suppository 1-2 times/day, up to 4 doses/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suppository: Belladonna extract 16.2 mg and opium 30 mg; belladonna extract 16.2 mg and opium 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F139441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1000012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Rectal: Remove from foil; moisten finger and suppository; insert rectally",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1000002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; avoid freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to severe pain associated with rectal or bladder tenesmus that may occur in postoperative states and neoplastic situations; relief of pain associated with ureteral spasms not responsive to non-narcotic analgesics and to space intervals between injections of opiates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       B&amp;O may be confused with beano&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F139445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central  nervous system: Dizziness, drowsiness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, photophobia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to belladonna, atropine, opium alkaloids, morphine, or any component; glaucoma; severe renal or hepatic disease; obstructive uropathy; obstructive disease of the GI tract; severe respiratory depression; convulsive disorders; acute alcoholism; premature labor",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2888905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution in patients with cardiac, respiratory, hepatic, or renal dysfunction, severe prostatic hypertrophy, or history of narcotic abuse; use with caution in patients with increased intracranial pressure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opium shares the toxic potential of opiate agonists; usual precautions of opiate agonist therapy should be observed; not recommended for use in children &lt;12 years",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F999999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid ethanol (may increase sedation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3025133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this product. Refer to Atropine and Morphine Sulfate monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1000004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic alkaloids act primarily by competitive inhibition of the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic neurons and on smooth muscle; resulting effects include antisecretory activity on exocrine glands and intestinal mucosa and smooth muscle relaxation. Contains many narcotic alkaloids including morphine; its mechanism for gastric motility inhibition is primarily due to this morphine content; it results in a decrease in digestive secretions, an increase in GI muscle tone, and therefore a reduction in GI propulsion.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2888906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Opium:  Onset of action: Within 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1000006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Metabolism: Hepatic",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1000016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/35/12852?source=see_link\">",
"      see \"Belladonna and opium: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug may cause physical and/or psychological dependence; avoid abrupt discontinuation after prolonged use. Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13204 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41636=[""].join("\n");
var outline_f40_42_41636=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999981\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000009\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139411\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139395\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139441\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000012\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000002\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999982\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139445\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999985\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888905\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999986\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298823\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999999\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139407\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3025133\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000004\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2888906\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000006\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1000016\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/41/26261?source=related_link\">",
"      Belladonna and opium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/35/12852?source=related_link\">",
"      Belladonna and opium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41637="Bundle branch reentrant ventricular tachycardia";
var content_f40_42_41637=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bundle branch reentrant ventricular tachycardia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     David J Callans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41637/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/42/41637/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bundle branch reentrant ventricular tachycardia (BBRVT) is a unique arrhythmia because the tachycardia circuit is dependent exclusively on the specialized conduction system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This has two important implications: a large portion of the circuit can be recorded directly, and the circuit is uniquely sensitive to the effects of focal ablation. The circuit involves antegrade conduction over the right bundle branch and retrograde conduction over the left bundle branch; the His bundle is adjacent to but separate from the circuit.",
"   </p>",
"   <p>",
"    BBRVT can be very rapid (often &gt;200 bpm), often resulting in syncope or cardiac arrest. It is a relatively rare arrhythmia, usually seen in patients with advanced structural heart disease, and it forms part of the differential diagnosis of wide complex tachycardias (in addition to myocardial VT, SVT with aberrancy of the left bundle branch, pre-excited tachycardias using nodofascicular or atrial fascicular bypass tracts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\", section on 'Causes of WCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related disorder, intrafascicular reentry, utilizes the separate fascicles of the left bundle branch. It, too, is typically observed in patients with advanced structural heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Both arrhythmias depend on conduction delay in the His Purkinje system.",
"   </p>",
"   <p>",
"    The mechanisms, clinical features, and treatment of BBRVT will be discussed here. The general approach to wide QRS complex tachycardias as well as the treatment of VT of other etiologies (ie, ischemic, scar-related) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM AND THE RESULTANT ELECTROCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In sinus rhythm, most patients with BBRVT have a prolonged QRS (nonspecific conduction delay or left bundle branch block), and most have a prolonged His to ventricle (HV) interval. It is important to consider that although we speak of left bundle branch block as an electrocardiographic pattern, the phenomena is typically a delay rather than a block, as retrograde complete left bundle branch block would make this arrhythmia circuit impossible. The arrhythmia begins when one or more premature ventricular beats arise and conduct into both the right bundle branch, where retrograde activation is blocked due to refractoriness from the preceding normally conducted antegrade beat, and into the left bundle branch, which has a shorter refractory period than the right bundle branch (",
"    <a class=\"graphic graphic_figure graphicRef75164 \" href=\"mobipreview.htm?4/55/4976\">",
"     figure 1",
"    </a>",
"    ). As a result, the impulse conducts retrogradely up the left bundle branch to the bundle of His, although the His bundle is not an essential component of the circuit. The impulse then conducts antegradely down the right bundle branch, activating the ventricle at the termination of the right bundle branch. For this reason, the QRS during VT has an LBBB pattern and may closely resemble the sinus rhythm QRS if baseline LBBB is present. If the timing is right and slow conduction through the circuit allows for recovery from refractoriness of all of the component parts, sustained reentry may be established.",
"   </p>",
"   <p>",
"    HV interval prolongation during sinus rhythm is common in patients with BBRVT, and a prolonged HV interval has been put forth as a prerequisite for developing sustained reentry within the bundle branches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/2,7-10\">",
"     2,7-10",
"    </a>",
"    ]. However, HV prolongation in sinus rhythm is not present in all cases, suggesting that BBRVT can result from functional conduction abnormalities in the His-Purkinje system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19126553\">",
"    <span class=\"h1\">",
"     ELECTROCARDIOGRAPHIC AND ELECTROPHYSIOLOGIC CHARACTERISTICS OF BBRVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;BBRVT is recognized by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LBBB morphology (although so-called \"reverse\" BBRVT may also occur, with activation of the ventricles over the left bundle branch, producing a RBBB QRS morphology)",
"     </li>",
"     <li>",
"      The HV interval during VT is typically longer than during sinus rhythm",
"     </li>",
"     <li>",
"      During spontaneous changes in cycle length, changes in the H-H interval precede and predict changes in the V-V interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antegrade conduction down the right bundle branch with delayed depolarization of the left ventricle results in a ventricular tachycardia with a typical LBBB appearance (",
"    <a class=\"graphic graphic_waveform graphicRef67679 \" href=\"mobipreview.htm?32/12/32967\">",
"     waveform 1A",
"    </a>",
"    ). In some patients, however, the reverse sequence of conduction occurs, leading a RBBB appearance. The PR interval may be normal or prolonged. The mean electrical axis is usually about +30&ordm;, but a conduction defect in the left anterior fascicle will produce a marked leftward (superior) axis deviation (",
"    <a class=\"graphic graphic_figure graphicRef79400 \" href=\"mobipreview.htm?8/17/8473\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most patients have a similar ECG during sinus rhythm because of the underlying prolongation of the HV interval (",
"    <a class=\"graphic graphic_waveform graphicRef67679 \" href=\"mobipreview.htm?32/12/32967\">",
"     waveform 1A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;BBRVT, usually seen in patients with advanced structural heart disease, occurs with both ischemic and nonischemic heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The heart disease is usually severe with cardiomegaly and a history of heart failure. Presyncope and syncope are common presenting symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of BBRVT is suggested from the surface electrocardiogram (ECG). However, VT of other types and supraventricular tachycardias with a preceding BBB, functional BBB, or preexcitation may also have an LBBB appearance. BBRVT has a rather \"typical\" LBBB pattern as does a supraventricular tachycardia with preexisting or functional BBB. In comparison, an \"atypical\" LBBB pattern (slurring of the initial QRS forces) favors myocardial ventricular tachycardia or pre-excited tachycardia.",
"   </p>",
"   <p>",
"    While the presence of BBRVT may be suspected from the surface ECG, definitively establishing the diagnosis often requires electrophysiologic testing to differentiate this arrhythmia from other forms of ventricular tachycardia. The general approach to wide complex tachycardias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is frequently necessary in BBRVT, since BBRVT typically occurs in the presence of significant heart disease and often leads to hemodynamic compromise and presyncope or syncope. Because of the high risk of recurrence with antiarrhythmic drug therapy, we prefer catheter ablation as the therapy of choice for BBRVT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;BBRVT is often resistant to antiarrhythmic drug therapy. In one study of seven patients, for example, four presented with syncope and three with aborted sudden death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/7\">",
"     7",
"    </a>",
"    ]. The patients, who had been unsuccessfully treated with two to four antiarrhythmic drugs, were successfully treated with catheter ablation of the right bundle branch.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to the lack of efficacy with antiarrhythmic drug therapy, catheter ablation effectively and safely eliminates BBRVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/3,4,6-8,12-14\">",
"     3,4,6-8,12-14",
"    </a>",
"    ]. We agree with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for the management of ventricular arrhythmias and the prevention of sudden cardiac death, which recommend catheter ablation of the right bundle branch for patients with BBRVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition to catheter ablation, many such patients will still have an indication for implantable cardioverter-defibrillator (ICD) implantation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'ICD therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most commonly, catheter ablation of the right bundle branch is performed, leading to complete RBBB. In this procedure, a catheter is inserted into the femoral vein and passed through the tricuspid valve until a right bundle electrogram is recorded. Both DC shock and radiofrequency ablation have been used with success and we consider ablation to be the treatment of choice (",
"    <a class=\"graphic graphic_waveform graphicRef67679 graphicRef77331 graphicRef66372 graphicRef80017 \" href=\"mobipreview.htm?40/25/41370\">",
"     waveform 1A-D",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    BBRVT has also been treated by ablation of the left bundle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/16\">",
"     16",
"    </a>",
"    ]. This provides the theoretical advantage of preventing the need for pacing, as the relatively normal right bundle branch remains unaffected; however, since the majority of patients with BBRVT require ICD therapy anyway (see below), and because this is more difficult than ablating the right bundle, it is seldom performed. Reentrant fascicular tachycardia has also been treated successfully using ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ICD therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following catheter ablation for BBRVT, repeat electrophysiologic testing generally reveals an inability to induce BBRVT. However, ventricular tachycardia of myocardial origin can be induced in some cases, although only a small number of patients have been studied. Because of the concurrent underlying structural heart disease, outcomes are often quite poor in patients followed after successful ablation of BBRVT. Sudden cardiac death (SCD) has been reported, and progressive heart failure is frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Due to the severity of underlying cardiac disease, many patients are candidates for ICD therapy for the primary or secondary prevention of SCD following catheter ablation for BBRVT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41637/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link&amp;anchor=H26#H26\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link&amp;anchor=H26#H26\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6850878\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bundle branch reentrant ventricular tachycardia (BBRVT) is a unique arrhythmia because the tachycardia circuit is dependent exclusively on the specialized conduction system. The circuit involves antegrade conduction over the right bundle branch and retrograde conduction over the left bundle branch; the His bundle is adjacent to but separate from the circuit. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with BBRVT typically have advanced structural heart disease, either ischemic or nonischemic heart disease. Presyncope and syncope are the common presenting symptoms of BBRVT. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of BBRVT is suggested from the surface electrocardiogram (ECG), on which BBRVT has a rather \"typical\" LBBB pattern. While the presence of BBRVT may be suspected from the surface ECG, definitively establishing the diagnosis often requires electrophysiologic testing to differentiate this arrhythmia from other forms of ventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H19126553\">",
"       'Electrocardiographic and electrophysiologic characteristics of BBRVT'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is frequently necessary in BBRVT, since BBRVT typically occurs in the presence of significant heart disease and often leads to hemodynamic compromise and presyncope or syncope. Because of the high risk of recurrence with antiarrhythmic drug therapy, we prefer catheter ablation as the therapy of choice for BBRVT. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending on the severity of concurrent underlying structural heart disease in patients with BBRVT, many patients are candidates for ICD therapy for the primary or secondary prevention of sudden cardiac death following catheter ablation for BBRVT. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'ICD therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/1\">",
"      Lloyd EA, Zipes DP, Heger JJ, Prystowsky EN. Sustained ventricular tachycardia due to bundle branch reentry. Am Heart J 1982; 104:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/2\">",
"      Caceres J, Jazayeri M, McKinnie J, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation 1989; 79:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/3\">",
"      Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycardias. Pacing Clin Electrophysiol 2011; 34:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/4\">",
"      Delacretaz E, Stevenson WG, Ellison KE, et al. Mapping and radiofrequency catheter ablation of the three types of sustained monomorphic ventricular tachycardia in nonischemic heart disease. J Cardiovasc Electrophysiol 2000; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/5\">",
"      Crijns HJ, Smeets JL, Rodriguez LM, et al. Cure of interfascicular reentrant ventricular tachycardia by ablation of the anterior fascicle of the left bundle branch. J Cardiovasc Electrophysiol 1995; 6:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/6\">",
"      Lopera G, Stevenson WG, Soejima K, et al. Identification and ablation of three types of ventricular tachycardia involving the his-purkinje system in patients with heart disease. J Cardiovasc Electrophysiol 2004; 15:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/7\">",
"      Cohen TJ, Chien WW, Lurie KG, et al. Radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia: results and long-term follow-up. J Am Coll Cardiol 1991; 18:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/8\">",
"      Blanck Z, Dhala A, Deshpande S, et al. Bundle branch reentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc Electrophysiol 1993; 4:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/9\">",
"      Merino JL, Peinado R, Fern&aacute;ndez-Lozano I, et al. Transient entrainment of bundle-branch reentry by atrial and ventricular stimulation: elucidation of the tachycardia mechanism through analysis of the surface ECG. Circulation 1999; 100:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/10\">",
"      Merino JL, Peinado R, Fernandez-Lozano I, et al. Bundle-branch reentry and the postpacing interval after entrainment by right ventricular apex stimulation: a new approach to elucidate the mechanism of wide-QRS-complex tachycardia with atrioventricular dissociation. Circulation 2001; 103:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/11\">",
"      Li YG, Gr&ouml;nefeld G, Israel C, et al. Bundle branch reentrant tachycardia in patients with apparent normal His-Purkinje conduction: the role of functional conduction impairment. J Cardiovasc Electrophysiol 2002; 13:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/12\">",
"      Tchou P, Jazayeri M, Denker S, et al. Transcatheter electrical ablation of right bundle branch. A method of treating macroreentrant ventricular tachycardia attributed to bundle branch reentry. Circulation 1988; 78:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/13\">",
"      Volkmann H, K&uuml;hnert H, Dannberg G, Heinke M. Bundle branch reentrant tachycardia treated by transvenous catheter ablation of the right bundle branch. Pacing Clin Electrophysiol 1989; 12:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/14\">",
"      Tai YT, Lee KL. Pleomorphic ventricular tachycardia with antegrade His-bundle activation: elucidation by multiple His-bundle recordings. J Cardiovasc Electrophysiol 1994; 5:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/15\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/16\">",
"      Blanck Z, Deshpande S, Jazayeri MR, Akhtar M. Catheter ablation of the left bundle branch for the treatment of sustained bundle branch reentrant ventricular tachycardia. J Cardiovasc Electrophysiol 1995; 6:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/17\">",
"      Blanck Z, Akhtar M. Ventricular tachycardia due to sustained bundle branch reentry: diagnostic and therapeutic considerations. Clin Cardiol 1993; 16:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/18\">",
"      Mehdirad AA, Keim S, Rist K, Tchou P. Long-term clinical outcome of right bundle branch radiofrequency catheter ablation for treatment of bundle branch reentrant ventricular tachycardia. Pacing Clin Electrophysiol 1995; 18:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41637/abstract/19\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 899 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41637=[""].join("\n");
var outline_f40_42_41637=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6850878\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM AND THE RESULTANT ELECTROCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19126553\">",
"      ELECTROCARDIOGRAPHIC AND ELECTROPHYSIOLOGIC CHARACTERISTICS OF BBRVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ICD therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6850878\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/899|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/55/4976\" title=\"figure 1\">",
"      Mechanism of bundle branch reentrant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/17/8473\" title=\"figure 2\">",
"      EP study in BBRVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/899|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?32/12/32967\" title=\"waveform 1A\">",
"      ECG bundle branch reentrant ventricular tachcardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/21/30035\" title=\"waveform 1B\">",
"      EP study tracings bundle branch reentrant VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?10/10/10403\" title=\"waveform 1C\">",
"      EP study tracings BBRVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?29/54/30563\" title=\"waveform 1D\">",
"      EP study tracings RBB ablation for BBRVT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41638="Indications for renal biopsy in patients with lupus nephritis";
var content_f40_42_41638=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Indications for renal biopsy in patients with lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41638/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/42/41638/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement occurs in approximately 60 percent of patients with systemic lupus erythematosus and is a major source of morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/1\">",
"     1",
"    </a>",
"    ]. There are multiple different histologic subtypes of lupus nephritis (LN) and the optimal treatment varies with the subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the clinical presentation, urinalysis and estimates of renal function may suggest a specific subtype, renal biopsy is necessary to confirm the correct classification category or class.",
"   </p>",
"   <p>",
"    The indications for renal biopsy among patients already diagnosed with SLE will be reviewed here. The various types and classifications of lupus nephritis, their treatment, and the management of patients with end-stage renal disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=see_link\">",
"     \"End-stage renal disease due to lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Society of Nephrology (ISN) pathologic classification scheme for lupus nephritis (LN) is discussed in detail separately but will be reviewed here. The ISN classification is a modification of an older system that was developed by the World Health Organization (WHO) and is still widely used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ISN classification divides the glomerular disorders of lupus into six main different classes or patterns, with subcategorizations based on activity and chronicity of the lesions by light microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these disorders tend to have distinct histologic, clinical, and prognostic characteristics, there is substantial overlap between the classes, based in part upon variations in sampling. In addition, a significant percentage of patients evolve from one form to another, both spontaneously and after therapy. In one series, for example, the probability of a transition from membranous to combined membranous and proliferative LN at was 35 percent at ten years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/4\">",
"     4",
"    </a>",
"    ]. This observation is not surprising, since the different histologic types of lupus nephritis represent nonspecific responses to immune complex deposition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and therapy of membranous lupus nephritis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Minimal mesangial LN (class I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal mesangial LN is the earliest and mildest form of glomerular involvement. The glomeruli are normal by light microscopy, but immunofluorescence and electron microscopy reveal mesangial immune deposits. Affected patients typically have a normal urinalysis and serum creatinine concentration. As a result, renal biopsy is not performed and the diagnosis is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mesangial proliferative LN (class II)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light microscopy in class II disease reveals mesangial hypercellularity (of any degree)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mesangial matrix expansion (",
"    <a class=\"graphic graphic_picture graphicRef80250 \" href=\"mobipreview.htm?27/46/28393\">",
"     picture 1",
"    </a>",
"    ). Electron dense deposits are detected in the mesangium by immunofluorescence and electron microscopy. The presence of subendothelial deposits on light microscopy (a few isolated subendothelial and subepithelial deposits may be seen on immunofluorescence or electron microscopy) or global or segmental glomerular scars (which are thought reflect previous endocapillary proliferation, necrosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    crescents) are inconsistent with the diagnosis, and indicate either class III or IV disease.",
"   </p>",
"   <p>",
"    Patients with class II disease typically present with microscopic hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria; hypertension is uncommon and the nephrotic syndrome and renal insufficiency are virtually never seen unless the patient progresses to more advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Focal proliferative LN (class III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In class III disease, fewer than 50 percent of glomeruli have active or inactive, segmental or global (less than or more than 50 percent of the tuft, respectively) endocapillary or extracapillary glomerulonephritis on light microscopy. These lesions are usually associated with focal subendothelial deposits on electron microscopy and mesangial changes may also be present.",
"   </p>",
"   <p>",
"    Hematuria and proteinuria are seen in almost all patients with class III disease, some of whom also have the nephrotic syndrome, hypertension, and an elevated serum creatinine concentration. The variable clinical presentation may in part reflect an inability to accurately determine the percent of glomeruli involved (and therefore to distinguish between focal and diffuse proliferative disease) due to the potential for sampling error induced by the relatively small number of glomeruli that are typically obtained with percutaneous renal biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diffuse proliferative LN (class IV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In class IV disease, more than 50 percent of glomeruli on light microscopy have active or inactive, segmental or global endocapillary or extracapillary glomerulonephritis, including necrotizing lesions and mesangial involvement (",
"    <a class=\"graphic graphic_picture graphicRef60218 \" href=\"mobipreview.htm?25/53/26457\">",
"     picture 2",
"    </a>",
"    ). Segmental (IV-S) and global (IV-G) diffuse lupus nephritis are defined by more than 50 percent of affected glomeruli having segmental and global lesions, respectively. With active disease, proliferative and necrotizing lesions and crescent formation all may be present. At least during the active phase, immunofluorescence microscopy reveals diffuse immunoglobulin and complement deposition (",
"    <a class=\"graphic graphic_picture graphicRef70781 \" href=\"mobipreview.htm?24/47/25328\">",
"     picture 3",
"    </a>",
"    ) and electron microscopy reveals subendothelial deposits.",
"   </p>",
"   <p>",
"    Hematuria and proteinuria are seen in nearly all patients with active class IV disease, and the nephrotic syndrome, hypertension, and renal insufficiency are all common. These patients typically have significant hypocomplementemia and elevated anti-DNA levels, especially in patients with active disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Membranous LN (class V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class V disease is characterized pathologically and clinically by many findings similar to those in idiopathic membranous nephropathy: diffuse thickening of the glomerular capillary wall on light microscopy (",
"    <a class=\"graphic graphic_picture graphicRef56549 \" href=\"mobipreview.htm?19/14/19689\">",
"     picture 4",
"    </a>",
"    ); and subepithelial immune deposits (either global or segmental) on immunofluorescence or electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef69348 \" href=\"mobipreview.htm?38/39/39543\">",
"     picture 5",
"    </a>",
"    ). However, in membranous LN, mesangial involvement is typically present, and includes mesangial proliferation observed by light microscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immune mesangial deposits observed by immunofluorescence and electron microscopy.",
"   </p>",
"   <p>",
"    Patients with pure membranous LN typically present with signs of the nephrotic syndrome, similar to that in idiopathic membranous nephropathy. Microscopic hematuria and hypertension also may be seen at presentation, and the serum creatinine concentration is usually normal or only slightly elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent class III or IV proliferative LN can occur in patients with class V membranous LN, and are designated as combined disease (eg, class III and V, or class IV and V). Patients with concurrent proliferative and membranous LN have a more active sediment and may have an elevated serum creatinine concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Advanced sclerosing LN (class VI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In class VI disease, more than 90 percent of glomeruli are globally sclerosed. The scarring represents healing of prior inflammatory injury, as well as the advanced stage of chronic class III, IV, or V lupus nephritis.",
"   </p>",
"   <p>",
"    Patients with sclerosing glomerulonephritis usually display slowly progressive renal dysfunction in association with proteinuria and typically some hematuria. Identification of class VI disease is important since immunosuppressive therapy is unlikely to be beneficial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of other renal lesions that can be seen in patients with systemic lupus erythematosus in addition to glomerular disease. These include acute tubulointerstitial nephritis (almost always seen with concurrent glomerular disease), vascular disease (eg, thrombotic microangiopathy or vasculitis), drug-induced lupus, lupus podocytopathy, and concurrent renal disease unrelated to lupus (eg, diabetes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/5\">",
"     5",
"    </a>",
"    ]. These lesions may have important therapeutic and prognostic significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Other'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=see_link\">",
"     \"Drug-induced lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Silent LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lupus who have no clinical evidence of renal disease may have lupus nephritis on renal biopsy, including diffuse proliferative disease. This entity is called silent lupus nephritis. These patients are not identified in routine clinical practice since renal biopsy is not performed in patients with no evidence of renal disease. The available data suggest that these patients will either manifest clinical disease or have a benign long-term prognosis with improvement in or resolution of histologic findings on repeat biopsy. Some develop overt disease, always in association with the development of an active urine sediment. There are no data that suggest that treating such patients alters clinical outcomes as long as there is no clinical evidence of active disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\", section on 'Silent lupus nephritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RATIONALE FOR RENAL BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A renal biopsy is performed in almost all lupus patients who have clinical or laboratory evidence of renal involvement (eg, abnormal proteinuria, active urine sediment, elevated serum creatinine",
"    <span class=\"nowrap\">",
"     and/",
"    </span>",
"    or decreased GFR) to determine the histologic subtype of lupus nephritis (LN). As noted above, the different subtypes have a different prognosis and may be treated differently.",
"   </p>",
"   <p>",
"    Renal biopsy is necessary in patients with lupus and evidence of renal disease because the clinical presentation may not accurately reflect the histologic findings, as illustrated by the following examples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/2,6,7\">",
"     2,6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with nephrotic syndrome and a bland sediment are likely to have membranous LN but may also have evidence on biopsy of a proliferative glomerulonephritis.",
"     </li>",
"     <li>",
"      Patients with an active sediment, no or low-grade proteinuria, a normal serum creatinine, and a normal blood pressure are likely to have minimal mesangial or focal proliferative LN, but may have diffuse proliferative disease.",
"     </li>",
"     <li>",
"      Patients with an elevated serum creatinine, an active urine sediment (red cells, white cells, and cellular casts), and nephrotic range proteinuria almost certainly have diffuse proliferative LN, but may also have marked crescent formation, which might alter selection of",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      response to therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal biopsy also allows identification of the presence and severity of associated tubulointerstitial disease and concurrent vascular disease or thrombi (as might be seen with antiphospholipid syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its role in patients with established lupus, renal biopsy may provide a diagnosis in patients with renal disease in whom the diagnosis of lupus is uncertain, such as patients with nephrotic or non-nephrotic proteinuria without an active urinary sediment and with mild or no evidence of serological activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally perform a renal biopsy in patients who have one or both of the following clinical manifestations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Protein excretion greater than 500",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      An active urinary sediment with hematuria (five or more red blood cells per high power field, most of which are dysmorphic) and cellular casts. The urine may be contaminated with vaginal blood in menstruating women. Red cells from this source are not dysmorphic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lupus patients who have an inactive sediment and less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of proteinuria are unlikely to have focal or diffuse proliferative or membranous lupus nephritis (LN). They may have minimal mesangial or mesangial proliferative disease, neither of which requires immunosuppressive treatment.",
"   </p>",
"   <p>",
"    Such patients should be followed for evidence of progressive disease such as increasing proteinuria, emergence of an active sediment,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increase in serum creatinine. These manifestations suggest transformation to a more severe lesion and warrant renal biopsy.",
"   </p>",
"   <p>",
"    In patients with an inactive sediment and less than 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of proteinuria, we suggest performing a urinalysis every three to six months for three years; every three months is preferred in patients with anti-double-stranded DNA antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypocomplementemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Timing of initial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal biopsy should be performed promptly (ie, within days to weeks) in patients who have an appropriate indication. Prompt diagnosis after the onset of lupus nephritis (LN) and subsequent initiation of appropriate therapy are associated with improved outcomes, regardless of the histologic class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. A rapidly rising serum creatinine is an indication for urgent renal biopsy so appropriate treatment can be initiated as soon as possible.",
"   </p>",
"   <p>",
"    The potential magnitude of the increase in risk with delayed renal biopsy was illustrated in a study of 91 patients with LN followed for a median of six years. Patients who had clinically recognized renal disease for &ge;6 months prior to biopsy had a much higher rate of end-stage renal disease (47 versus 14 per 1000 patient-years for those who had an earlier biopsy; hazard ratio 9.3, 95% CI 1.8-47.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/11\">",
"     11",
"    </a>",
"    ]. Similar findings were noted in another report in which the relative risk for subsequent renal insufficiency was 4.9 in patients with a delay between the time of detection of renal disease and first renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have raised the question of whether renal biopsy might be delayed for one or two months with careful monitoring in patients with mild manifestations of nephritis. However, NONE of the authors or peer reviews of this topic review delays renal biopsy in such patients, since delayed diagnosis has been associated with worse outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link&amp;anchor=H3#H3\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Delayed therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Repeat biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for a repeat biopsy include the emergence of an active sediment in someone with previously quiescent disease, a new elevation in serum creatinine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening of proteinuria despite treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/4,14-16\">",
"     4,14-16",
"    </a>",
"    ]. In a report from a single institution, transformation from one histologic pattern to another was noted in more than one-half of patients who underwent repeat renal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of repeat biopsy depends in part upon the histologic diagnosis obtained on the initial biopsy. Among patients with membranous lupus, a repeat biopsy is warranted for those who develop an active sediment since this suggests transformation to a proliferative lesion, which usually requires different treatment. In a retrospective study of 29 patients with membranous lupus, the probability of a transition from membranous to proliferative nephritis at ten years was 35 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast, recurrence of proteinuria generally is NOT an indication for repeat biopsy in membranous LN, since relapse of isolated proteinuria is common, especially after immunosuppressive therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features and therapy of membranous lupus nephritis\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features and therapy of membranous lupus nephritis\", section on 'NIH trial of cyclophosphamide versus cyclosporine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A repeat biopsy is NOT usually necessary in patients with successfully treated diffuse proliferative disease who develop a recurrent active sediment that almost certainly represents recurrent proliferative disease. Renal biopsy is unlikely to provide any additional data that would affect treatment in most such patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Settings in which repeat renal biopsy might be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing proteinuria which, in one report, was the indication for repeat biopsy in 45 of 57 patients with LN who had at least two renal biopsies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/16\">",
"       16",
"      </a>",
"      ]. As an example, new or worsening nephrotic syndrome in patients with treated proliferative LN may reflect a concurrent membranous lesion and combined proliferative and membranous LN may be best treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil and a calcineurin inhibitor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=see_link&amp;anchor=H15#H15\">",
"       \"Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis\", section on 'Diffuse proliferative plus membranous LN'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An active sediment and a rapidly rising serum creatinine, which might reflect crescentic disease that requires more aggressive initial therapy.",
"     </li>",
"     <li>",
"      Slowly rising serum creatinine in patients, particularly blacks, who also have a urine sediment suggesting possible low grade disease activity (eg, 10 red cells per high power field without red cell or other cellular casts). The goal of repeat biopsy is to distinguish active proliferative LN from advanced sclerosing LN (class VI) alone, which would not be treated with immunosuppressive therapy.",
"     </li>",
"     <li>",
"      Suspicion of possible renal disease unrelated to lupus (eg, drug-induced acute interstitial nephritis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue from recurrent active LN is slowly progressive chronic kidney disease that may represent nonimmunologic injury induced by nephron loss from previous inflammatory disease, with subsequent intraglomerular hypertension and hyperfiltration. Such patients present with a gradual increase in protein excretion (non-nephrotic), a bland urine sediment without hematuria, and a gradual increase in serum creatinine. In a study of 45 patients who had a repeat renal biopsy for the evaluation of increasing proteinuria, the most common finding was a decrease in proliferative lesions and an increase in chronic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41638/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not usually perform repeat renal biopsy in these patients in whom treatment consists of blockade of the renin-angiotensin-aldosterone system and optimal blood pressure control, not immunosuppressive therapy. However, continued monitoring for signs of active renal disease is recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus among the authors and reviewers of this topic on possible indications for repeat renal biopsy to detect active disease in such patients. Mentioned findings include the presence of antiphospholipid antibodies (which can cause renal disease with a bland urine sediment), active extrarenal lupus, and markedly elevated anti-dsDNA antibody titers with or without hypocomplementemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=see_link&amp;anchor=H4#H4\">",
"     \"Antiphospholipid syndrome and the kidney\", section on 'Renal disease in APS associated with SLE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are six main classes of lupus nephritis. The optimal treatment and prognosis varies with the class and subcategory. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification and clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A renal biopsy is necessary to determine the optimal immunosuppressive therapy since the class and subcategory cannot always be predicted from the clinical presentation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rationale for renal biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend performing a renal biopsy in patients with lupus who have protein excretion greater than 500",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an active urinary sediment with hematuria (typically dysmorphic), and, in some patients, cellular casts. Such patients are most likely to have focal or diffuse proliferative glomerulonephritis or membranous lupus. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a repeat renal biopsy for patients with one or more of the following features: a newly active urine sediment after a period of disease quiescence; a rapidly rising serum creatinine (which might reflect crescentic disease); new or worsening nephrotic syndrome in those treated for proliferative lupus nephritis since such patients may have developed a concurrent membranous lesion that may require different therapy; a slowly rising serum creatinine in patients who also have a urine sediment suggesting possible low grade disease activity; or suspicion of possible renal disease unrelated to lupus (eg, drug-induced acute interstitial nephritis). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Repeat biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/1\">",
"      Beck LH Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J Am Soc Nephrol 2009; 20:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/2\">",
"      Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol 2010; 21:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/3\">",
"      Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/4\">",
"      Mercadal L, Montcel ST, Nochy D, et al. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002; 17:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/5\">",
"      Baranowska-Daca E, Choi YJ, Barrios R, et al. Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum Pathol 2001; 32:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/6\">",
"      Ponticelli C, Moroni G. Renal biopsy in lupus nephritis--what for, when and how often? Nephrol Dial Transplant 1998; 13:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/7\">",
"      Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/8\">",
"      Jennette JC, Iskandar SS, Dalldorf FG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int 1983; 24:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/9\">",
"      Adu D, Williams DG, Taube D, et al. Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis. Q J Med 1983; 52:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/10\">",
"      Christopher-Stine L, Siedner M, Lin J, et al. Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 2007; 34:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/11\">",
"      Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/12\">",
"      Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994; 21:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/13\">",
"      Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus 2005; 14:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/14\">",
"      Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 1999; 78:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/15\">",
"      Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999; 34:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/16\">",
"      Bajaj S, Albert L, Gladman DD, et al. Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 2000; 27:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41638/abstract/17\">",
"      Austin HA 3rd, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009; 20:901.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3087 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41638=[""].join("\n");
var outline_f40_42_41638=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION AND CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Minimal mesangial LN (class I)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mesangial proliferative LN (class II)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Focal proliferative LN (class III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diffuse proliferative LN (class IV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Membranous LN (class V)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Advanced sclerosing LN (class VI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Silent LN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RATIONALE FOR RENAL BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Timing of initial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Repeat biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3087|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28393\" title=\"picture 1\">",
"      SLE Mesangial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/53/26457\" title=\"picture 2\">",
"      SLE Proliferative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/47/25328\" title=\"picture 3\">",
"      SLE Proliferative IF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/14/19689\" title=\"picture 4\">",
"      SLE Membranous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/39/39543\" title=\"picture 5\">",
"      SLE Membranous EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35287?source=related_link\">",
"      Antiphospholipid syndrome and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28168?source=related_link\">",
"      Drug-induced lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12345?source=related_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41639="Uterotonic drugs for management of the third stage of labor";
var content_f40_42_41639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Uterotonic drugs for management of the third stage of labor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Frank Silverman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Eran Bornstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41639/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/42/41639/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third stage of labor refers to the interval from delivery of the baby to separation and expulsion of the placenta. The major complications of the third stage of labor are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemorrhage (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"       \"Overview of postpartum hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=see_link\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Retained placenta (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35208?source=see_link\">",
"       \"Diagnosis and management of retained placenta after vaginal birth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Uterine inversion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8743?source=see_link\">",
"       \"Puerperal uterine inversion\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss use of uterotonic drugs to minimize blood loss and prevent postpartum hemorrhage. Other aspects of management of the third stage, such as the procedure for delivery of the placenta, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=see_link&amp;anchor=H14958846#H14958846\">",
"     \"Management of normal labor and delivery\", section on 'Third stage of labor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACTIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active management is the preferred approach to management of the third stage of labor because it reduces mean blood loss and the rate of postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Despite evidence from randomized trials supporting various protocols for active management of the third stage, these protocols have been underutilized in the United States and Latin America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Multifaceted behavioral intervention (including interactive workshops, hands-on training, clinical reminders, and feedbacks) can increase adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Active management has generally consisted of prophylactic administration of an uterotonic agent prior to placental separation, early cord clamping, and controlled cord traction; uterine massage also may be performed. However, contemporary data show that the uterotonic agent is the most important component of this package [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In cases when uterotonic agents are not available or are declined by the patient, breast feeding might reduce the incidence of postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits and risks of active management were illustrated in a systematic review (seven trials, n = 8247 women) comparing active versus expectant management (four trials) or a mixture of managements (three trials) of the third stage of labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/1\">",
"       1",
"      </a>",
"      ]. Active management was defined as administration of a prophylactic uterotonic agent before delivery of the placenta; typically with early cord",
"      <span class=\"nowrap\">",
"       clamping/cutting",
"      </span>",
"      and controlled traction of the umbilical cord. Expectant or physiologic management was spontaneous delivery of the placenta without the use of uterotonic agents or cord traction. Major findings were:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In general obstetrical populations, active management was associated with reduced risks of severe maternal hemorrhage (&gt;1000 mL: RR 0.34, 95% CI 0.14-0.87;",
"      <span class=\"nowrap\">",
"       8/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       24/1000;",
"      </span>",
"      three trials, 4636 women) and postpartum maternal hemoglobin &lt;9",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (RR 0.50, 95% CI 0.30-0.83;",
"      <span class=\"nowrap\">",
"       36/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       71/1000;",
"      </span>",
"      two trials, 1572 women) compared to expectant management.",
"     </li>",
"     <li>",
"      Active management was also associated with a significant decrease in primary blood loss &gt;500 mL (RR 0.34, 95% CI 0.27-0.42), mean maternal blood loss at birth (-79 mL, 95% CI -96 to -62 mL), maternal blood transfusion (RR 0.35, 95% CI 0.22-0.55), and use of therapeutic uterotonics during the third stage or within the first 24 hours, or both (RR 0.19, 95% CI 0.15-0.23).",
"     </li>",
"     <li>",
"      However, there were also statistically significant increases in maternal diastolic blood pressure &gt;90 mmHg (RR 4.10), after-pains and use of analgesia (RR 2.53), and number of women returning to the hospital because of bleeding (RR 2.21) compared with expectant management. &nbsp;",
"     </li>",
"     <li>",
"      In women at low risk of postpartum bleeding, findings were similar to those in the general obstetrical population except the reduction in severe hemorrhage was no longer significant.",
"     </li>",
"     <li>",
"      The length of the third stage was similar for both active and expectant management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DRUGS USED FOR ACTIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    for active management of the third stage of labor. We do not give uterotonic drugs until after delivery of the anterior fetal shoulder to ensure that shoulder dystocia, if present, is not exacerbated. In patients who have not had an ultrasound examination, it is important to confirm the absence of an undiagnosed and undelivered twin before initiating active management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is a major component of active management of the third stage of labor. The value of oxytocin was shown in a systematic review (seven trials, n = 3000 patients) that compared prophylactic administration of oxytocin to no uterotonic agents in the third stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients treated with oxytocin demonstrated a significant reduction in mean blood loss and postpartum hemorrhage (blood loss &gt;500 mL: RR 0.50, 95% CI 0.43-0.59; blood loss &gt;1000 mL: RR 0.61, 95% CI 0.44-0.87) and need for therapeutic oxytocics (RR 0.50, 95% CI 0.39-0.64). There was no difference between groups in the length of the third stage.",
"   </p>",
"   <p>",
"    The benefits of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    need to be balanced against the adverse effects, which are dose related and include hypotension, tachycardia, increased cardiac output, myocardial ischemia, flushing, nausea, vomiting, and mild antidiuresis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H117029624\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum timing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    administration is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/12\">",
"     12",
"    </a>",
"    ]. It has been given before placental separation to expedite the process and after placental expulsion to enhance contraction of the uterus and reduce the volume of blood loss. Most randomized trials have administered the drug prior to placental separation (after delivery of the anterior shoulder); there are fewer data on administration after placental expulsion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A survey of Canadian obstetricians reported 52 percent of respondents administered",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      prior to delivery of the placenta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/13\">",
"       13",
"      </a>",
"      ]. A similar questionnaire given to 1500 obstetricians in Texas found that only 15 percent administered oxytocics prior to delivery of the placenta, whereas 92 percent did so after placental expulsion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/14\">",
"       14",
"      </a>",
"      ]. Local treatment protocols, staff availability, and obstetrical training may have been the reason for the geographical variation.",
"     </li>",
"     <li>",
"      A trial comparing the two regimens included 1486 women who were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (20 units in 500 mL of normal saline) upon delivery of the anterior shoulder or after delivery of the placenta [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/15\">",
"       15",
"      </a>",
"      ]. A modified Brandt maneuver was performed in all patients. There were no significant differences between the two groups in blood loss or retained placenta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32572018\">",
"    <span class=\"h3\">",
"     Route and dose",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14962691\">",
"    <span class=\"h4\">",
"     Intravenous infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    is usually infused into a maternal vein. The dose and duration of intravenous oxytocin infusion as a prophylactic agent vary widely among institutions. A commonly used dose is 10 to 20 units of oxytocin per 500 mL 0.9 percent saline, with the rate of infusion adjusted, as needed, to prevent uterine atony [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Higher doses have been studied, but did not demonstrate a clear benefit. In a randomized trial comparing two oxytocin doses (80",
"    <span class=\"nowrap\">",
"     units/500",
"    </span>",
"    mL versus 10",
"    <span class=\"nowrap\">",
"     units/500",
"    </span>",
"    mL infused over one hour), there was no significant difference between the doses in the composite outcome of atony or hemorrhage requiring treatment (uterotonic drugs, transfusion, tamponade, embolization, surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of strong evidence favoring one dose over another, it is the author&rsquo;s practice to infuse 20 units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    in one liter of fluid at a rate of 125",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    following delivery of the placenta. This is generally continued for eight hours in order to complete the one liter infusion. The section editor uses a dose of 40 units of oxytocin.",
"   </p>",
"   <p>",
"    If postpartum uterine bleeding is not excessive and the mother is stable in the postpartum unit, the infusion is usually discontinued upon completion of the infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14962705\">",
"    <span class=\"h4\">",
"     Intramuscular administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative efficacy of intramuscular versus intravenous prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    has not been evaluated in randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/19\">",
"     19",
"    </a>",
"    ]. Observational data and clinical experience indicate that intramuscular administration of up to 10 units oxytocin is an effective alternative to intravenous infusion if there is no intravenous access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/20\">",
"     20",
"    </a>",
"    ]. Onset of action is slower, three to five minutes versus less than one minute with the intravenous route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14962766\">",
"    <span class=\"h4\">",
"     Intravenous bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     Oxytocin",
"    </a>",
"    (1 to 10 units) given as an intravenous bolus is effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/16,17,21,22\">",
"     16,17,21,22",
"    </a>",
"    ], but the safety of this route has been questioned due to reports of significant hypotension that may lead to cardiovascular collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29060471\">",
"    <span class=\"h5\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least two trials in women undergoing cesarean delivery reported that bolus injection (&ldquo;IV push&rdquo;) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    was associated with ischemic electrocardiogram changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The minimum effective bolus dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    after cesarean is unclear, but appears to be &le;3 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/11,27\">",
"     11,27",
"    </a>",
"    ]. Even a 2.5 unit bolus of oxytocin can produce adverse effects, including tachycardia and hypotension, in preeclamptic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/28\">",
"     28",
"    </a>",
"    ]. A systematic review of randomized trials that attempted to determine the optimal initial dose of oxytocin to prevent postpartum hemorrhage after cesarean delivery in low risk women suggested that those who underwent scheduled cesarean delivery receive a 0.3 to 1 unit bolus over one minute and those who underwent cesarean delivery during labor receive a 3 unit bolus over one minute; in both settings they suggested following the bolus with an oxytocin infusion of 5 to 10",
"    <span class=\"nowrap\">",
"     units/hour",
"    </span>",
"    for four hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/11\">",
"     11",
"    </a>",
"    ]. If the initial bolus injection was not effective, they suggested repeating it once or twice and then trying a different uterotonic drug.",
"   </p>",
"   <p>",
"    If a bolus injection is given after cesarean delivery, the addition of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    infusion appears to reduce blood loss and the need for blood transfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    additional uterotonic agents compared to bolus injection alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. However, the combination of a bolus injection and an infusion does not appear to reduce the need for additional uterotonic agents compared to use of an infusion alone, despite causing an initially stronger uterine contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/31\">",
"     31",
"    </a>",
"    ]. Therefore, we suggest an oxytocin infusion without a bolus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14962725\">",
"    <span class=\"h4\">",
"     Injection into an umbilical vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized trials concluded that umbilical vein injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    was not effective for prevention of postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ergot alkaloids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ergot alkaloids can be administered as single agent therapy, most commonly as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    0.2 mg intramuscularly. These drugs are contraindicated in women with hypertension, history of migraine, or Raynaud's phenomenon.",
"   </p>",
"   <p>",
"    A systematic review (six trials, n = 3941 women) found ergot alkaloids used alone in the third stage of labor significantly decreased mean blood loss (weighted mean difference -83 mL, 95% CI -99 to -67 mL) and the risk of postpartum hemorrhage &ge;500 mL (RR 0.38, 95% CI 0.21-0.69) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major disadvantage of these agents is that they are associated with an increased frequency of vomiting, blood pressure elevation, and pain requiring analgesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/3\">",
"     3",
"    </a>",
"    ]. The injectable ergometrine is very unstable when stored unrefrigerated or exposed to light, which limits its use in rural areas of developing countries.",
"   </p>",
"   <p>",
"    Several investigators have compared the prophylactic use of ergot alkaloids to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . A systematic review (six trials, n = 2800 women) comparing these two drugs did not find a significant difference in blood loss between them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the use of oxytocin was associated with fewer manual removals of the placenta and fewer side effects.",
"   </p>",
"   <p>",
"    Ergot preparations are associated with more side effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    because they act systemically on smooth muscle, while oxytocin is specific for uterine smooth muscle. However, they are longer lasting and produce more tetanic contractions than oxytocin, thus they are particularly useful for treatment of postpartum hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Ergometrine-oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined ergometrine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    preparation (ie, Syntometrine&reg;: 5 units oxytocin plus 0.5 mg ergometrine, not available in the United States) has been successfully used in the active management of the third stage of labor, but does not appear to have a clinically important advantage over oxytocin alone and is associated with more side effects.",
"   </p>",
"   <p>",
"    A systematic review (six trials, n = 9332 women) determined that the use of ergometrine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    was associated with a small but statistically significant reduction in the risk of postpartum hemorrhage of 500 to 1000 mL compared with oxytocin alone (OR 0.82, 95% CI 0.71-0.95), but no difference in risk of postpartum hemorrhage &gt;1000 mL or in the duration of the third stage of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/33\">",
"     33",
"    </a>",
"    ]. Maternal side effects, such as significant nausea, vomiting, and hypertension in previously normotensive women, were more commonly associated with the use of ergometrine-oxytocin than with oxytocin alone. Data on neonatal complications were limited, but did not show any difference between the two groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins given orally, sublingually, or per rectum are less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    or ergometrine given parenterally for active management of the third stage of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/4\">",
"     4",
"    </a>",
"    ]. Few studies have compared parenteral prostaglandins with parenteral uterotonics.",
"   </p>",
"   <p>",
"    In a systematic review, use of sublingual",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    (prostaglandin E1) was more effective than placebo or no treatment for reducing the frequency of severe postpartum hemorrhage &gt;1000 mL (RR severe hemorrhage 0.31, 95% CI 0.10-0.94; four trials, 3519 women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/4\">",
"     4",
"    </a>",
"    ]. Due to significant heterogeneity, data from seven trials evaluating oral misoprostol administration versus",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment were not pooled; findings from these trials were discordant. Only one trial compared rectal misoprostol with",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment and did not find a statistical benefit.",
"   </p>",
"   <p>",
"    In the systematic review, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    was less effective than injectable uterotonics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    , ergometrine), as it was associated with a higher risk of severe postpartum hemorrhage &gt;1000 mL than these drugs (RR 1.33, 95% CI 1.16-1.52; 17 trials, n = 29,797 women). Rectal misoprostol was not more effective than injectable uterotonics (RR of severe hemorrhage: 1.10, 95% CI 0.69-1.77; four trials, 2221 women). Data on the comparative efficacy of the sublingual route versus injectable uterotonics were limited (three trials, n = 270 women), and did not show a statistical benefit (RR severe hemorrhage: 0.54, 95% CI 0.23-1.27).",
"   </p>",
"   <p>",
"    Common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    include shivering and fever. Misoprostol-related fever is usually preceded by shivering, begins within 20 minutes of administration, peaks at one to two hours, and spontaneously declines over three hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/34\">",
"     34",
"    </a>",
"    ]. The incidence of fever varies by dose and route of administration, and is most common in patients receiving high-dose sublingual misoprostol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/35\">",
"     35",
"    </a>",
"    ]. In one small pharmacodynamic study, 8 percent of patients receiving 200 or 400 mcg sublingual misoprostol developed fever over 39 degrees Celsius, while 45 percent of those receiving 600 mcg became febrile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on the data discussed above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and ergometrine, where available, are preferable to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    for active management of the third stage of labor. Use of misoprostol, however, has some advantages: it is inexpensive, easy to administer, and does not require refrigeration. Thus, use of misoprostol is advantageous in resource-limited countries where drugs that must be refrigerated or require needles for",
"    <span class=\"nowrap\">",
"     injection/intravenous",
"    </span>",
"    administration may pose a problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/37-44\">",
"     37-44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oxytocin agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"     Carbetocin",
"    </a>",
"    , a long-acting synthetic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    agonist, has similar pharmacologic properties to those of natural oxytocin. It binds to smooth muscle receptors of the uterus and causes rhythmic contractions, increases the frequency of contractions, and increases uterine tone. It is available in many countries (but not in the United States) for prevention of uterine atony and hemorrhage. A potential advantage of carbetocin over oxytocin is its longer duration of action.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"     Carbetocin",
"    </a>",
"    100 mcg may be given by a single slow intravenous injection. The toxicity spectrum is similar to that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . Therefore, it seems reasonable to use this drug as an alternative to oxytocin in countries where it is available, as it is easy to administer and has a long duration of action.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review compared the risk of postpartum hemorrhage in patients receiving prophylactic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"       carbetocin",
"      </a>",
"      (100 micrograms as an intravenous bolus) versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (varying doses) in the third stage of labor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The risk of postpartum hemorrhage &gt;500 mL was similar for both groups, although the trend suggested a potential benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"       carbetocin",
"      </a>",
"      use at cesarean (RR 0.66, 95% CI 0.42-1.06; four trials, 1195 women), but not vaginal delivery (RR 0.95, 95% CI 0.43-2.09; one trial, 131 women).",
"     </li>",
"     <li>",
"      In women who underwent cesarean delivery, the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"       carbetocin",
"      </a>",
"      was associated with a reduction in the subsequent need for therapeutic uterotonic agents (RR 0.64, 95% CI 0.51-0.81), but not in those who underwent vaginal delivery (RR 0.93; 95% CI 0.44-1.94; one trial, 160 women).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"       Carbetocin",
"      </a>",
"      reduced the need for uterine massage postdelivery after both cesarean (RR 0.64, 95% CI 0.31-0.96) and vaginal delivery (RR 0.70, 95% CI 0.51-0.94).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/45/33491?source=see_link\">",
"       Carbetocin",
"      </a>",
"      was as effective as Syntometrine&reg; for prevention of postpartum hemorrhage &gt;500 mL (RR 1.0; 95% CI 0.48-2.07), but was associated with significantly less nausea and vomiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2178774103\">",
"    <span class=\"h2\">",
"     Tranexamic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of two randomized trials found that administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    (0.5 or 1 gram intravenously) significantly decreased mean postpartum blood loss and the risk of postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/46\">",
"     46",
"    </a>",
"    ]. In one trial, the drug was given immediately after vaginal delivery, and, in the other trial, it was given 10 minutes prior to incision for cesarean birth. The trials were of unclear quality and looked at only a few outcomes. Further investigation of the safety and efficacy of this approach is needed, given the increased risk of venous and arterial thrombosis with use of this drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10246284\">",
"    <span class=\"h2\">",
"     Poor medical resource settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Countries with limited resources may lack the uterotonic medications described above or the appropriate means to store them. Nipple stimulation might reduce the incidence of postpartum hemorrhage by promoting the release of endogenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/10\">",
"     10",
"    </a>",
"    ]. This safe, inexpensive and easy to apply intervention is suggested when uterotonics are not available or are declined by the patient.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    is an inexpensive uterotonic drug that is easy to administer and does not require refrigeration or needles for",
"    <span class=\"nowrap\">",
"     injection/intravenous",
"    </span>",
"    administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41639/abstract/37-43\">",
"     37-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active management of the third stage reduces maternal blood loss and risk of postpartum hemorrhage. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Active management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      or the combined ergometrine-oxytocin preparation (ie, Syntometrine&reg;, not available in the United States) for the uterotonic agent rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest oxytocin rather than ergometrine-oxytocin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When compared to oxytocin alone, ergometrine-oxytocin appears to be associated with a small reduction in the risk of postpartum hemorrhage &ge;500 to 1000 mL, but an increase in side effects (vomiting, hypertension). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oxytocin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      infusion into a maternal vein rather than bolus intravenous injection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), as the latter can cause ischemic electrocardiogram changes, cardiovascular collapse, and cardiac arrest. In the absence of intravenous access, intramuscular injection (up to 10 units) is reasonable. Intraumbilical vein injection is not effective. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oxytocin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32572018\">",
"       'Route and dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are insufficient data to determine whether administration of the uterotonic agent is more effective if it is given after delivery of the anterior shoulder but before separation of the placenta or immediately upon expulsion of the placenta. We give a relatively rapid infusion of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (20 units in 1000 mL crystalloid) upon delivery of the anterior shoulder (to limit the risk of shoulder dystocia). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Oxytocin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/1\">",
"      Begley CM, Gyte GM, Devane D, et al. Active versus expectant management for women in the third stage of labour. Cochrane Database Syst Rev 2011; :CD007412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/2\">",
"      Elbourne DR, Prendiville WJ, Carroli G, et al. Prophylactic use of oxytocin in the third stage of labour. Cochrane Database Syst Rev 2001; :CD001808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/3\">",
"      Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam QM. Prophylactic use of ergot alkaloids in the third stage of labour. Cochrane Database Syst Rev 2007; :CD005456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/4\">",
"      Tun&ccedil;alp &Ouml;, Hofmeyr GJ, G&uuml;lmezoglu AM. Prostaglandins for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2012; 8:CD000494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/5\">",
"      Belizan M, Meier A, Althabe F, et al. Facilitators and barriers to adoption of evidence-based perinatal care in Latin American hospitals: a qualitative study. Health Educ Res 2007; 22:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/6\">",
"      Festin MR, Lumbiganon P, Tolosa JE, et al. International survey on variations in practice of the management of the third stage of labour. Bull World Health Organ 2003; 81:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/7\">",
"      Althabe F, Buekens P, Bergel E, et al. A behavioral intervention to improve obstetrical care. N Engl J Med 2008; 358:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/8\">",
"      Hofmeyr GJ, Abdel-Aleem H, Abdel-Aleem MA. Uterine massage for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2008; :CD006431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/9\">",
"      G&uuml;lmezoglu AM, Lumbiganon P, Landoulsi S, et al. Active management of the third stage of labour with and without controlled cord traction: a randomised, controlled, non-inferiority trial. Lancet 2012; 379:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/10\">",
"      Irons DW, Sriskandabalan P, Bullough CH. A simple alternative to parenteral oxytocics for the third stage of labor. Int J Gynaecol Obstet 1994; 46:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/11\">",
"      Stephens LC, Bruessel T. Systematic review of oxytocin dosing at caesarean section. Anaesth Intensive Care 2012; 40:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/12\">",
"      Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev 2010; :CD006173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/13\">",
"      Baskett, T. Management of the third stage of labor: a survey of practice among Canadian obstetricians. J Soc Obstet Gynecol Can 1992; 14:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/14\">",
"      Phillips CA, Kinch RA. Management of the third stage of labor: a survey of practice among Texas obstetricians. Tex Med 1994; 90:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/15\">",
"      Jackson KW Jr, Allbert JR, Schemmer GK, et al. A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage. Am J Obstet Gynecol 2001; 185:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/16\">",
"      Davies GA, Tessier JL, Woodman MC, et al. Maternal hemodynamics after oxytocin bolus compared with infusion in the third stage of labor: a randomized controlled trial. Obstet Gynecol 2005; 105:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/17\">",
"      Nordstr&ouml;m L, Fogelstam K, Fridman G, et al. Routine oxytocin in the third stage of labour: a placebo controlled randomised trial. Br J Obstet Gynaecol 1997; 104:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/18\">",
"      Tita AT, Szychowski JM, Rouse DJ, et al. Higher-dose oxytocin and hemorrhage after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2012; 119:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/19\">",
"      Oladapo OT, Okusanya BO, Abalos E. Imtramuscular versus intravenous prophylactic oxytocin for the third stage of labor. Cochrane Database Syst Rev 2012; :CD009331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/20\">",
"      Saito K, Haruki A, Ishikawa H, et al. Prospective study of intramuscular ergometrine compared with intramuscular oxytocin for prevention of postpartum hemorrhage. J Obstet Gynaecol Res 2007; 33:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/21\">",
"      Balki M, Ronayne M, Davies S, et al. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstet Gynecol 2006; 107:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/22\">",
"      Pierre F, Mesnard L, Body G. For a systematic policy of i.v. oxytocin inducted placenta deliveries in a unit where a fairly active management of third stage of labour is yet applied: results of a controlled trial. Eur J Obstet Gynecol Reprod Biol 1992; 43:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/23\">",
"      Archer TL, Knape K, Liles D, et al. The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases. Int J Obstet Anesth 2008; 17:247.",
"     </a>",
"    </li>",
"    <li>",
"     Why Mothers Die 1977-1999. The confidential enquiries into maternal deaths in the United Kingdom. RCOG Press, London 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/25\">",
"      Jonsson M, Hanson U, Lidell C, Nord&eacute;n-Lindeberg S. ST depression at caesarean section and the relation to oxytocin dose. A randomised controlled trial. BJOG 2010; 117:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/26\">",
"      Svanstr&ouml;m MC, Biber B, Hanes M, et al. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. Br J Anaesth 2008; 100:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/27\">",
"      Butwick AJ, Coleman L, Cohen SE, et al. Minimum effective bolus dose of oxytocin during elective Caesarean delivery. Br J Anaesth 2010; 104:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/28\">",
"      Dyer RA, Piercy JL, Reed AR, et al. Hemodynamic changes associated with spinal anesthesia for cesarean delivery in severe preeclampsia. Anesthesiology 2008; 108:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/29\">",
"      Sheehan SR, Montgomery AA, Carey M, et al. Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial. BMJ 2011; 343:d4661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/30\">",
"      G&uuml;ng&ouml;rd&uuml;k K, Asicioglu O, Celikkol O, et al. Use of additional oxytocin to reduce blood loss at elective caesarean section: A randomised control trial. Aust N Z J Obstet Gynaecol 2010; 50:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/31\">",
"      King KJ, Douglas MJ, Unger W, et al. Five unit bolus oxytocin at cesarean delivery in women at risk of atony: a randomized, double-blind, controlled trial. Anesth Analg 2010; 111:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/32\">",
"      Mori R, Nardin JM, Yamamoto N, et al. Umbilical vein injection for the routine management of third stage of labour. Cochrane Database Syst Rev 2012; 3:CD006176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/33\">",
"      McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine-oxytocin versus oxytocin for the third stage of labour. Cochrane Database Syst Rev 2004; :CD000201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/34\">",
"      Durocher J, Bynum J, Le&oacute;n W, et al. High fever following postpartum administration of sublingual misoprostol. BJOG 2010; 117:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/35\">",
"      Elati A, Weeks A. Risk of fever after misoprostol for the prevention of postpartum hemorrhage: a meta-analysis. Obstet Gynecol 2012; 120:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/36\">",
"      Elati A, Elmahaishi MS, Elmahaishi MO, et al. The effect of misoprostol on postpartum contractions: a randomised comparison of three sublingual doses. BJOG 2011; 118:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/37\">",
"      Lokugamage AU, Sullivan KR, Niculescu I, et al. A randomized study comparing rectally administered misoprostol versus Syntometrine combined with an oxytocin infusion for the cessation of primary post partum hemorrhage. Acta Obstet Gynecol Scand 2001; 80:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/38\">",
"      Cali��kan E, Meydanli MM, Dilbaz B, et al. Is rectal misoprostol really effective in the treatment of third stage of labor? A randomized controlled trial. Am J Obstet Gynecol 2002; 187:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/39\">",
"      H&oslash;j L, Cardoso P, Nielsen BB, et al. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ 2005; 331:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/40\">",
"      Enakpene CA, Morhason-Bello IO, Enakpene EO, et al. Oral misoprostol for the prevention of primary post-partum hemorrhage during third stage of labor. J Obstet Gynaecol Res 2007; 33:810.",
"     </a>",
"    </li>",
"    <li>",
"     Parsons, SM, Walley, RL, Crane, JM, Matthews, K, Hutchens, D. Rectal misoprostol versus oxytocin in the management of the third stage of labour.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/42\">",
"      Derman RJ, Kodkany BS, Goudar SS, et al. Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial. Lancet 2006; 368:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/43\">",
"      Mobeen N, Durocher J, Zuberi N, et al. Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial. BJOG 2011; 118:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/44\">",
"      Hundley VA, Avan BI, Sullivan CJ, Graham WJ. Should oral misoprostol be used to prevent postpartum haemorrhage in home-birth settings in low-resource countries? A systematic review of the evidence. BJOG 2013; 120:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/45\">",
"      Su LL, Chong YS, Samuel M. Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2012; 4:CD005457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41639/abstract/46\">",
"      Novikova N, Hofmeyr GJ. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010; :CD007872.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4437 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-188.40.116.55-F65976BBC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41639=[""].join("\n");
var outline_f40_42_41639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACTIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DRUGS USED FOR ACTIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H117029624\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32572018\">",
"      - Route and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14962691\">",
"      Intravenous infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14962705\">",
"      Intramuscular administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14962766\">",
"      Intravenous bolus",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H29060471\">",
"      - Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14962725\">",
"      Injection into an umbilical vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ergot alkaloids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Ergometrine-oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oxytocin agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2178774103\">",
"      Tranexamic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10246284\">",
"      Poor medical resource settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35208?source=related_link\">",
"      Diagnosis and management of retained placenta after vaginal birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8743?source=related_link\">",
"      Puerperal uterine inversion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41640="Epidemiology and clinical manifestations of Scedosporium infection";
var content_f40_42_41640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of Scedosporium infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Sylvia F Costa, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Barbara D Alexander, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41640/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/42/41640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past few decades, opportunistic fungal pathogens have become increasingly recognized as a cause of infection in severely ill or immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although Aspergillus species remains the most common mould to cause invasive infection, other mould infections, such as Scedosporium, are becoming more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Two members of this genus, Scedosporium apiospermum and Scedosporium prolificans, are considered major human pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and clinical manifestations of Scedosporium infections will be reviewed here. The diagnosis and treatment of these infections other emerging fungal infections are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33302?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYCOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth of Scedosporium species has been extensively studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The ability of this organism to grow on medium with cycloheximide is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/6\">",
"     6",
"    </a>",
"    ], and this factor may be used as a means of differentiating S. apiospermum from S. prolificans, which is unable to grow in the presence of this compound.",
"   </p>",
"   <p>",
"    Both species grow optimally between 30&ordm;C to 37&ordm;C within 48 to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/6\">",
"     6",
"    </a>",
"    ]; their specific colony characteristics are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Scedosporium apiospermum",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/7\">",
"     7",
"    </a>",
"    ] is the &nbsp;asexual form (anamorph) of Pseudallescheria boydii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/5,6,8,9\">",
"     5,6,8,9",
"    </a>",
"    ]. Colonies on cornmeal agar are rapid growing and cottony in appearance; with age, the colonies become gray or brown in color (",
"    <a class=\"graphic graphic_picture graphicRef52899 \" href=\"mobipreview.htm?36/36/37440\">",
"     picture 1",
"    </a>",
"    ). The hyphal forms &nbsp;appear as branching septate hyphae with a single terminal conidia, which is uninucleate and cylindrical in shape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/10\">",
"     10",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef74529 \" href=\"mobipreview.htm?4/30/4577\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When the sexual form is present in culture, the organism is identified as P. boydii. Dark, spherical structures, known as cleistothecia, characterize this sexual form of this organism &nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef62333 \" href=\"mobipreview.htm?8/53/9043\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Scedosporium prolificans",
"    </span>",
"    &nbsp;&mdash;&nbsp;When first isolated as a human pathogen, S. prolificans was initially called Scedosporium inflatum due to its basally swollen, flask-shaped conidiogenous cells (",
"    <a class=\"graphic graphic_picture graphicRef63775 \" href=\"mobipreview.htm?28/11/28849\">",
"     picture 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast to S. apiospermum, no sexual form has been identified for S. prolificans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colony characteristics differ based on which nutrient agar is used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. On Sabouraud's dextrose medium, the colony is white and cottony with the reverse side appearing greenish gray to dark green [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12\">",
"     12",
"    </a>",
"    ]; colonies on potato dextrose agar are flat and olive gray to black in color [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/10\">",
"     10",
"    </a>",
"    ]. Conidiogenous cells may form singly or in small clusters along the vegetative hyphae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scedosporium mould species are found ubiquitously in the environment, including in soil and polluted water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/5,6,8,9,13,14\">",
"     5,6,8,9,13,14",
"    </a>",
"    ]. Both species have a global distribution including Europe, Australia, and the United States; S. apiospermum (and P. boydii) have also been isolated in South America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/5,8,15-23\">",
"     5,8,15-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Human infection often results from inhalation of spores from the environment into the lungs or paranasal sinuses, or through direct inoculation, as in skin puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial outbreaks of Scedosporium infection in immunocompromised hosts have been linked to contaminated ambient air in hospital isolation rooms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/18,24-27\">",
"     18,24-27",
"    </a>",
"    ]. One such outbreak occurred at a time of hospital renovation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/18\">",
"     18",
"    </a>",
"    ]. Another report included six hematologic malignancy patients with neutropenia who were not in a laminar airflow room or high efficiency particulate absorbing (HEPA) filtered room when they developed infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/25\">",
"     25",
"    </a>",
"    ]. Scedosporium isolates from four patients and two air samples were identical by PCR fingerprinting. After the initiation of stricter infection control practices, as well as positive-pressure and HEPA filtration for hospital rooms, no further environmental contamination or clinical cases were reported in the subsequent two years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COLONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum is the second most common filamentous fungus isolated from the airway of cystic fibrosis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/28-31\">",
"     28-31",
"    </a>",
"    ] and may be a precipitant of inflammatory responses, similar to that seen in allergic bronchopulmonary aspergillosis. In addition to colonization of the airways, S. prolificans has also been cultured from the external auditory canal of patients without apparent clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scedosporium species can cause localized infection in the immunocompetent host following trauma or surgery or severe disseminated disease in the immunosuppressed host. The two species are discussed separately below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     S. apiospermum infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum is mainly associated with infections in the immunosuppressed host, although some localized infections have been described in immunocompetent hosts as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum infection frequently involves the respiratory tract in patients with underlying immunodeficiency, due to chronic granulomatous disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/32\">",
"     32",
"    </a>",
"    ], chronic steroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/33\">",
"     33",
"    </a>",
"    ], hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/21,34-38\">",
"     21,34-38",
"    </a>",
"    ], hematologic malignancy, or solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/20,21,39-43\">",
"     20,21,39-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial presentation typically includes fever, cough, sputum production, pleuritic chest pain, tachypnea, and malaise. Scedosporium infection may present as a localized pulmonary process or may disseminate from the lungs to multiple organs, including brain and skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/21,39,40\">",
"     21,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Keratitis and endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmologic Scedosporium infections can present as a localized corneal process or as endophthalmitis in the setting of disseminated disease.",
"   </p>",
"   <p>",
"    Fungal keratitis caused by Scedosporium spp has been reported in immunocompetent hosts with and without a history of overt ocular injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Patients may experience eye pain, photophobia, foreign body sensation, conjunctival or corneal erythema, tearing, and changes in visual acuity. Scedosporium corneal infections can lead to frank corneal ulceration, abrasion, perforation, infiltrate, and anterior chamber hypopion. Corneal scrapings or biopsy provide the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, endophthalmitis secondary to S. apiospermum can occur after hematologic dissemination in the immunosuppressed host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/39,49-56\">",
"     39,49-56",
"    </a>",
"    ]. Presenting symptoms may include eye pain, photosensitivity, and decreased visual acuity. Fundoscopic examination reveals exudates and a hazy vitreous; a haemorrhagic necrotizing chorioretinitis has been noted on autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum has been associated with brain abscesses in both immunocompetent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] and immunosuppressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/39,60,61\">",
"     39,60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. apiospermum brain abscesses have been described in individuals surviving near-drowning episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/59,62-65\">",
"     59,62-65",
"    </a>",
"    ]. The portal of entry may be directly through the sinuses with contiguous spread, or via hematogenous dissemination from the lung. Patients may be obtunded with low grade fever; the clinical picture can be complicated by severe hypoxia related to the near drowning event.",
"   </p>",
"   <p>",
"    Brain abscesses from hematologic dissemination of S. apiospermum have been described in immunosuppressed populations, particularly in recipients of hematopoietic stem cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/60,66,67\">",
"     60,66,67",
"    </a>",
"    ] and solid organ transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/39,54,55,68,69\">",
"     39,54,55,68,69",
"    </a>",
"    ]. Neurologic findings may include headache, confusion, disorientation, agitation, cognitive decline, progressive lethargy, hemiparesis, or tonic-clonic seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Skin, soft tissue and bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions secondary to S. apiospermum often occur in the setting of disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/21,39,68,70-73\">",
"     21,39,68,70-73",
"    </a>",
"    ]. Lesions may appear as nodules or as erythematous to purple papulae or bullae, which may develop a necrotic center. Occasionally, a pattern of lymphangitic spread may be seen with multiple nodules and pustules.",
"   </p>",
"   <p>",
"    Localized soft tissue infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/43,73,74\">",
"     43,73,74",
"    </a>",
"    ] and osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/58,75-77\">",
"     58,75-77",
"    </a>",
"    ] due to S. apiospermum (and P. boydii) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/15,78-84\">",
"     15,78-84",
"    </a>",
"    ] have also been reported in the setting of trauma. The extremities are most often involved, although cases involving the spine or cranium have also been described.",
"   </p>",
"   <p>",
"    Material from an aspiration or biopsy can be directly cultured to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated disease is typically defined as the presence of two or more non-contiguous body sites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bloodstream infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/72,85,86\">",
"     72,85,86",
"    </a>",
"    ]. Dissemination is known to readily occur, particularly in severely immunosuppressed patients and can cause shock and multiorgan failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. apiospermum has also been implicated as a cause of sinusitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/39,87,88\">",
"     39,87,88",
"    </a>",
"    ], lymphadenitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/89\">",
"     89",
"    </a>",
"    ], and mycotic aneurysm in a kidney transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     S. prolificans infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first described case of S. prolificans infection was in 1984, in an immunocompetent six-year old boy, who developed osteomyelitis of the foot after penetrating trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12\">",
"     12",
"    </a>",
"    ]. Since then, multiple cases with different clinical presentations have been reported in the literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16,17,19,22\">",
"     16,17,19,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Respiratory tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of the respiratory tract with S. prolificans has been reported mainly in patients with immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/17,20,21\">",
"     17,20,21",
"    </a>",
"    ]. Underlying conditions have included malignancy (usually hematologic), solid organ or hematopoietic stem cell transplantation (HSCT), chronic immunosuppressive therapy, chronic corticosteroid treatment, and AIDS. The usual presenting symptoms have included productive cough, dyspnea, and fever and the organism was recovered from either sputum or bronchoalveolar lavage specimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a group of lung transplant recipients, S. prolificans was repeatedly cultured from bronchoalveolar lavage fluid, often together with S. apiospermum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/20\">",
"     20",
"    </a>",
"    ]. The majority of these patients had the following characteristics, which may have predisposed them to infection: bacterial or CMV pneumonitis, rejection episodes requiring pulse steroids, and structural changes in their airways. Eradication of S. prolificans was unsuccessful in the majority of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Keratitis and endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. prolificans has been implicated as an agent of fungal keratitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/91-94\">",
"     91-94",
"    </a>",
"    ] and endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/57,95-97\">",
"     57,95-97",
"    </a>",
"    ]. Trauma or surgery may serve as a portal of entry for the fungus.",
"   </p>",
"   <p>",
"    Keratitis may present as foreign body sensation, lacrimation, and discharge. The cases described are in patients who either had a retained contact lens (which led to breakdown in the corneal epithelium), or who had experienced scleral necrosis after pterygium surgery with adjunctive beta-irradiation. If the corneal epithelium is invaded by the fungus, aggressive surgical debridement and antifungal therapy is needed to avoid loss of visual acuity or enucleation.",
"   </p>",
"   <p>",
"    Both exogenous and endogenous endophthalmitis have been reported, the latter in the setting of disseminated infection. Changes in visual acuity or other visual disturbances are reported, with fundoscopic exam revealing vitreous turbidity and white retinal infiltrates or exudates. Progressive visual loss is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Central nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system infection with S. prolificans has been reported in the setting of disseminated infection and has an extremely high mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16,21,98-101\">",
"     16,21,98-101",
"    </a>",
"    ]. CNS findings include headache, altered mental status, meningeal signs, focal neurologic deficits, seizures, or acute neurologic deterioration. Meningoencephalitis, encephalitis, and cerebral abscesses have been reported, with clinical findings correlating with brain imaging studies or autopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Skin, soft tissue and bone infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized musculoskeletal infections, such as fungal arthritis or osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12,19,22,102-104\">",
"     12,19,22,102-104",
"    </a>",
"    ] due to S. prolificans have been reported. The most frequent predisposing event is trauma, either penetrating or non-penetrating, to the affected extremity. Initial presentations include laceration or cellulitis at the site, with progression to joint effusion, inflammation, and tenderness; some patients also have low-grade fever. Those with bone involvement have symptoms and signs of inflammation, as well as imaging studies consistent with osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Disseminated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly reported presentation of S. prolificans is disseminated infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16-18,21,23,57,97-99,101,105-110\">",
"     16-18,21,23,57,97-99,101,105-110",
"    </a>",
"    ]. Fungemia is more common with S. prolificans than with S. apiospermum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/21\">",
"     21",
"    </a>",
"    ]. In three case series, positive blood cultures were reported in 80 percent",
"    <span class=\"nowrap\">",
"     (24/30),",
"    </span>",
"    75 percent",
"    <span class=\"nowrap\">",
"     (12/16),",
"    </span>",
"    and 100 percent",
"    <span class=\"nowrap\">",
"     (6/6)",
"    </span>",
"    of S. prolificans cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16,17,23\">",
"     16,17,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predisposing underlying risk factors for fungemia include neutropenia, HSCT, solid organ transplant, malignancy, and AIDS. In a series of neutropenic patients with hematologic malignancy, the most frequent clinical manifestation of disseminated S. prolificans infection was fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16\">",
"     16",
"    </a>",
"    ]. Pulmonary symptoms, such as dyspnea, cough, and infiltrates on chest radiographs, were also common. Other symptoms and signs included skin lesions, altered mental status, visual changes, renal failure, and septic shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both Scedosporium apiospermum and Scedosporium prolificans species grow optimally between 30&ordm;C to 37&ordm;C. They can be differentiated from one another by specific morphologic and growth characteristics. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mycology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scedosporium species are commonly found in soil and polluted water and have a global distribution. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scedosporium is mainly associated with infections in the immunosuppressed host, although some localized infections have been described in immunocompetent hosts as well. Case reports and series include pneumonia, keratitis, endophthalmitis, central nervous system infections, soft tissue infections, and disseminated disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/1\">",
"      Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 Suppl 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/2\">",
"      Perfect, JR, Schell, WA. The new fungal opportunists are coming. Clin Infect Dis 1996; 22 Suppl 2:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/3\">",
"      Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003; 37:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/4\">",
"      Panackal AA, Marr KA. Scedosporium/Pseudallescheria infections. Semin Respir Crit Care Med 2004; 25:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/5\">",
"      McGinnis, MR, Padhye, AA, Ajello, L. Pseudallescheria Negroni et Fischer, 1943 and its later synonym Petriellidium Malloch, 1970. Mycotaxon 1982; 14:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/6\">",
"      de Hoog GS, Marvin-Sikkema FD, Lahpoor GA, et al. Ecology and physiology of the emerging opportunistic fungi Pseudallescheria boydii and Scedosporium prolificans. Mycoses 1994; 37:71.",
"     </a>",
"    </li>",
"    <li>",
"     Castellani, A, Chalmers, AJ. Scedosporium apiospermum (Sacc.) Castell &amp; Chalm (1919). Manual of Tropical Medicine. 3rd edition ed. London: Baillere, Tindall &amp; Cox, 1919.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/8\">",
"      Rainer J, de Hoog GS, Wedde M, et al. Molecular variability of Pseudallescheria boydii, a neurotropic opportunist. J Clin Microbiol 2000; 38:3267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/9\">",
"      Gilgado F, Cano J, Gen&eacute; J, Guarro J. Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species. J Clin Microbiol 2005; 43:4930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/10\">",
"      Salkin IF, McGinnis MR, Dykstra MJ, Rinaldi MG. Scedosporium inflatum, an emerging pathogen. J Clin Microbiol 1988; 26:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/11\">",
"      Walsh TJ, Groll A, Hiemenz J, et al. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10 Suppl 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/12\">",
"      Malloch, D, Salkin, IF. A new species of Scedosporium associated with osteomyelitis in humans. Mycotaxon 1984; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/13\">",
"      Hennebert, GI, Desai, BG. Lomentospora prolificans, a new hyphomycete from greenhous soil. Mycotaxon 1974; 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/14\">",
"      Summerbell RC, Krajden S, Kane J. Potted plants in hospitals as reservoirs of pathogenic fungi. Mycopathologia 1989; 106:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/15\">",
"      Travis LB, Roberts GD, Wilson WR. Clinical significance of Pseudallescheria boydii: a review of 10 years' experience. Mayo Clin Proc 1985; 60:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/16\">",
"      Berenguer J, Rodr&iacute;guez-Tudela JL, Richard C, et al. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 1997; 76:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/17\">",
"      Idigoras P, P&eacute;rez-Trallero E, Pi&ntilde;eiro L, et al. Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2001; 32:E158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/18\">",
"      Alvarez M, Lopez Ponga B, Rayon C, et al. Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 1995; 33:3290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/19\">",
"      Wood GM, McCormack JG, Muir DB, et al. Clinical features of human infection with Scedosporium inflatum. Clin Infect Dis 1992; 14:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/20\">",
"      Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis 2001; 3:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/21\">",
"      Husain S, Mu&ntilde;oz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/22\">",
"      Wilson CM, O'Rourke EJ, McGinnis MR, Salkin IF. Scedosporium inflatum: clinical spectrum of a newly recognized pathogen. J Infect Dis 1990; 161:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/23\">",
"      Revankar SG, Patterson JE, Sutton DA, et al. Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis 2002; 34:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/24\">",
"      del Palacio A, Garau M, Amor E, et al. Case reports. Transient colonization with Scedosporium prolificans. Report of four cases in Madrid. Mycoses 2001; 44:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/25\">",
"      Guerrero A, Torres P, Duran MT, et al. Airborne outbreak of nosocomial Scedosporium prolificans infection. Lancet 2001; 357:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/26\">",
"      Simarro E, Mar&iacute;n F, Morales A, et al. Fungemia due to Scedosporium prolificans: a description of two cases with fatal outcome. Clin Microbiol Infect 2001; 7:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/27\">",
"      Cooley L, Spelman D, Thursky K, Slavin M. Infection with Scedosporium apiospermum and S. prolificans, Australia. Emerg Infect Dis 2007; 13:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/28\">",
"      Cimon B, Carr&egrave;re J, Vinatier JF, et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000; 19:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/29\">",
"      Symoens F, Knoop C, Schrooyen M, et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant 2006; 25:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/30\">",
"      Defontaine A, Zouhair R, Cimon B, et al. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 2002; 40:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/31\">",
"      Williamson EC, Speers D, Arthur IH, et al. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol 2001; 39:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/32\">",
"      Jabado N, Casanova JL, Haddad E, et al. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin Infect Dis 1998; 27:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/33\">",
"      Horr&eacute; R, Jovani�� B, Marklein G, et al. Fatal pulmonary scedosporiosis. Mycoses 2003; 46:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/34\">",
"      Garc&iacute;a-Arata MI, Otero MJ, Zome&ntilde;o M, et al. Scedosporium apiospermum pneumonia after autologous bone marrow transplantation. Eur J Clin Microbiol Infect Dis 1996; 15:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/35\">",
"      Klopfenstein KJ, Rosselet R, Termuhlen A, Powell D. Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation. Med Pediatr Oncol 2003; 41:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/36\">",
"      Nomded&eacute;u J, Brunet S, Martino R, et al. Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report. Clin Infect Dis 1993; 16:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/37\">",
"      Goldberg SL, Geha DJ, Marshall WF, et al. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993; 16:803.",
"     </a>",
"    </li>",
"    <li>",
"     Marr, KA, Carter, RA, Crippa, F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 200; 34:909.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/39\">",
"      Castiglioni B, Sutton DA, Rinaldi MG, et al. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) 2002; 81:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/40\">",
"      Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest 2002; 121:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/41\">",
"      Patterson TF, Andriole VT, Zervos MJ, et al. The epidemiology of pseudallescheriasis complicating transplantation: nosocomial and community-acquired infection. Mycoses 1990; 33:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/42\">",
"      Perlroth MG, Miller J. Pseudoallescheria boydii pneumonia and empyema: a rare complication of heart transplantation cured with voriconazole. J Heart Lung Transplant 2004; 23:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/43\">",
"      Talbot TR, Hatcher J, Davis SF, et al. Scedosporium apiospermum pneumonia and sternal wound infection in a heart transplant recipient. Transplantation 2002; 74:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/44\">",
"      D&iacute;az-Valle D, Benitez del Castillo JM, Amor E, et al. Severe keratomycosis secondary to Scedosporium apiospermum. Cornea 2002; 21:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/45\">",
"      Hern&aacute;ndez Prats C, Llinares Tello F, Burgos San Jos&eacute; A, et al. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 2004; 38:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/46\">",
"      Nulens E, Eggink C, Rijs AJ, et al. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol 2003; 41:2261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/47\">",
"      Wu Z, Ying H, Yiu S, et al. Fungal keratitis caused by Scedosporium apiospermum: report of two cases and review of treatment. Cornea 2002; 21:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/48\">",
"      del Palacio A, Perez-Blazquez E, Cu&eacute;tara MS, et al. Keratomycosis due to Scedosporium apiospermum. Mycoses 1991; 34:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/49\">",
"      Larocco A Jr, Barron JB. Endogenous scedosporium apiospermum endophthalmitis. Retina 2005; 25:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/50\">",
"      Caya JG, Farmer SG, Williams GA, et al. Bilateral Pseudallescheria boydii endophthalmitis in an immunocompromised patient. Wis Med J 1988; 87:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/51\">",
"      Figueroa MS, Fortun J, Clement A, De Ar&eacute;valo BF. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/52\">",
"      Leck A, Matheson M, Tuft S, et al. Scedosporium apiospermum keratomycosis with secondary endophthalmitis. Eye (Lond) 2003; 17:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/53\">",
"      Pfeifer JD, Grand MG, Thomas MA, et al. Endogenous Pseudallescheria boydii endophthalmitis. Clinicopathologic findings in two cases. Arch Ophthalmol 1991; 109:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/54\">",
"      Luu KK, Scott IU, Miller D, Davis JL. Endogenous Pseudallescheria boydii endophthalmitis in a patient with ring-enhancing brain lesions. Ophthalmic Surg Lasers 2001; 32:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/55\">",
"      Lopez FA, Crowley RS, Wastila L, et al. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: a case of mistaken identity. J Heart Lung Transplant 1998; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/56\">",
"      Fort&uacute;n J, Mart&iacute;n-D&aacute;vila P, S&aacute;nchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis 2003; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/57\">",
"      McKelvie PA, Wong EY, Chow LP, Hall AJ. Scedosporium endophthalmitis: two fatal disseminated cases of Scedosporium infection presenting with endophthalmitis. Clin Experiment Ophthalmol 2001; 29:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/58\">",
"      Horr&eacute; R, Feil E, Stangel AP, et al. [Scedosporiosis of the brain with fatal outcome after traumatizatio of the foot. case report]. Mycoses 2000; 43 Suppl 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/59\">",
"      R&uuml;chel R, Wilichowski E. Cerebral Pseudallescheria mycosis after near-drowning. Mycoses 1995; 38:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/60\">",
"      Safdar A, Papadopoulos EB, Young JW. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy. Transpl Infect Dis 2002; 4:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/61\">",
"      Montero A, Cohen JE, Fern&aacute;ndez MA, et al. Cerebral pseudallescheriasis due to Pseudallescheria boydii as the first manifestation of AIDS. Clin Infect Dis 1998; 26:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/62\">",
"      Mursch K, Trnovec S, Ratz H, et al. Successful treatment of multiple Pseudallescheria boydii brain abscesses and ventriculitis/ependymitis in a 2-year-old child after a near-drowning episode. Childs Nerv Syst 2006; 22:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/63\">",
"      Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole. Case report. J Neurosurg 2005; 103:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/64\">",
"      Kowacs PA, Soares Silvado CE, Monteiro de Almeida S, et al. Infection of the CNS by Scedosporium apiospermum after near drowning. Report of a fatal case and analysis of its confounding factors. J Clin Pathol 2004; 57:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/65\">",
"      Dworzack DL, Clark RB, Borkowski WJ Jr, et al. Pseudallescheria boydii brain abscess: association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses. Medicine (Baltimore) 1989; 68:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/66\">",
"      Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/67\">",
"      Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/68\">",
"      Montejo M, Mu&ntilde;iz ML, Z&aacute;rraga S, et al. Case Reports. Infection due to Scedosporium apiospermum in renal transplant recipients: a report of two cases and literature review of central nervous system and cutaneous infections by Pseudallescheria boydii/Sc. apiospermum. Mycoses 2002; 45:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/69\">",
"      Nesky MA, McDougal EC, Peacock Jr JE. Pseudallescheria boydii brain abscess successfully treated with voriconazole and surgical drainage: case report and literature review of central nervous system pseudallescheriasis. Clin Infect Dis 2000; 31:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/70\">",
"      Canet JJ, Pagerols X, S&aacute;nchez C, et al. Lymphocutaneous syndrome due to Scedosporium apiospermum. Clin Microbiol Infect 2001; 7:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/71\">",
"      Karaarslan A, Arikan S, Karaarslan F, Cetin ES. Skin infection caused by Scedosporium apiospermum. Mycoses 2003; 46:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/72\">",
"      Girmenia C, Luzi G, Monaco M, Martino P. Use of voriconazole in treatment of Scedosporium apiospermum infection: case report. J Clin Microbiol 1998; 36:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/73\">",
"      Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol 2005; 43:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/74\">",
"      Piper JP, Golden J, Brown D, Broestler J. Successful treatment of Scedosporium apiospermum suppurative arthritis with itraconazole. Pediatr Infect Dis J 1990; 9:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/75\">",
"      German JW, Kellie SM, Pai MP, Turner PT. Treatment of a chronic Scedosporium apiospermum vertebral osteomyelitis. Case report. Neurosurg Focus 2004; 17:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/76\">",
"      O'Doherty M, Hannan M, Fulcher T. Voriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host. Orbit 2005; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/77\">",
"      Levine NB, Kurokawa R, Fichtenbaum CJ, et al. An immunocompetent patient with primary Scedosporium apiospermum vertebral osteomyelitis. J Spinal Disord Tech 2002; 15:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/78\">",
"      Gatto J, Paterson D, Davis L, et al. Vertebral osteomyelitis due to Pseudallescheria boydii. Pathology 1997; 29:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/79\">",
"      Hung LH, Norwood LA. Osteomyelitis due to Pseudallescheria boydii. South Med J 1993; 86:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/80\">",
"      Kanafani ZA, Comair Y, Kanj SS. Pseudallescheria boydii cranial osteomyelitis and subdural empyema successfully treated with voriconazole: a case report and literature review. Eur J Clin Microbiol Infect Dis 2004; 23:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/81\">",
"      Lonser RR, Brodke DS, Dailey AT. Vertebral osteomyelitis secondary to Pseudallescheria boydii. J Spinal Disord 2001; 14:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/82\">",
"      Sopta J, Atanackovi�� M, Raspopovi�� V, et al. [Pseudoallescheria boydii (Scedosporium apiospermum), cause of mycotic granulomatous osteomyelitis--case diagnosis]. Srp Arh Celok Lek 2005; 133:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/83\">",
"      Dellestable F, Kures L, Mainard D, et al. Fungal arthritis due to Pseudallescheria boydii (Scedosporium apiospermum). J Rheumatol 1994; 21:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/84\">",
"      Fern&aacute;ndez-Guerrero ML, Ruiz Barn&eacute;s P, Al&eacute;s JM. Postcraniotomy mycetoma of the scalp and osteomyelitis due to Pseudallescheria boydii. J Infect Dis 1987; 156:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/85\">",
"      Mu&ntilde;oz P, Mar&iacute;n M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/86\">",
"      Riddell J 4th, Chenoweth CE, Kauffman CA. Disseminated Scedosporium apiospermum infection in a previously healthy woman with HELLP syndrome. Mycoses 2004; 47:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/87\">",
"      Eckburg PB, Zolopa AR, Montoya JG. Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS. Clin Infect Dis 1999; 29:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/88\">",
"      Machado CM, Martins MA, Heins-Vaccari EM, et al. Scedosporium apiospermum sinusitis after bone marrow transplantation: report of a case. Rev Inst Med Trop Sao Paulo 1998; 40:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/89\">",
"      Kiraz N, G&uuml;lbas Z, Akg&uuml;n Y, Uzun O. Lymphadenitis caused by Scedosporium apiospermum in an immunocompetent patient. Clin Infect Dis 2001; 32:E59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/90\">",
"      Ben Hamida M, Bedrossian J, Pruna A, et al. Fungal mycotic aneurysms and visceral infection due to Scedosporium apiospermum in a kidney transplant patient. Transplant Proc 1993; 25:2290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/91\">",
"      Arthur S, Steed LL, Apple DJ, et al. Scedosporium prolificans keratouveitis in association with a contact lens retained intraocularly over a long term. J Clin Microbiol 2001; 39:4579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/92\">",
"      Sullivan LJ, Snibson G, Joseph C, Taylor HR. Scedosporium prolificans sclerokeratitis. Aust N Z J Ophthalmol 1994; 22:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/93\">",
"      Kumar B, Crawford GJ, Morlet GC. Scedosporium prolificans corneoscleritis: a successful outcome. Aust N Z J Ophthalmol 1997; 25:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/94\">",
"      Moriarty AP, Crawford GJ, McAllister IL, Constable IJ. Fungal corneoscleritis complicating beta-irradiation-induced scleral necrosis following pterygium excision. Eye (Lond) 1993; 7 ( Pt 4):525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/95\">",
"      Taylor A, Wiffen SJ, Kennedy CJ. Post-traumatic Scedosporium inflatum endophthalmitis. Clin Experiment Ophthalmol 2002; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/96\">",
"      Vagefi MR, Kim ET, Alvarado RG, et al. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J Ophthalmol 2005; 139:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/97\">",
"      Maertens J, Lagrou K, Deweerdt H, et al. Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review. Ann Hematol 2000; 79:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/98\">",
"      Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/99\">",
"      Nenoff P, G&uuml;tz U, Tintelnot K, et al. Disseminated mycosis due to Scedosporium prolificans in an AIDS patient with Burkitt lymphoma. Mycoses 1996; 39:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/100\">",
"      Madrigal V, Alonso J, Bureo E, et al. Fatal meningoencephalitis caused by Scedosporium inflatum (Scedosporium prolificans) in a child with lymphoblastic leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/101\">",
"      Salesa R, Burgos A, Ondiviela R, et al. Fatal disseminated infection by Scedosporium inflatum after bone marrow transplantation. Scand J Infect Dis 1993; 25:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/102\">",
"      Steinbach WJ, Schell WA, Miller JL, Perfect JR. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. J Clin Microbiol 2003; 41:3981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/103\">",
"      Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/104\">",
"      Pickles RW, Pacey DE, Muir DB, Merrell WH. Experience with infection by Scedosporium prolificans including apparent cure with fluconazole therapy. J Infect 1996; 33:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/105\">",
"      de Batlle J, Motj&eacute; M, Balanz&agrave; R, et al. Disseminated infection caused by Scedosporium prolificans in a patient with acute multilineal leukemia. J Clin Microbiol 2000; 38:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/106\">",
"      Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/107\">",
"      Marin J, Sanz MA, Sanz GF, et al. Disseminated Scedosporium inflatum infection in a patient with acute myeloblastic leukemia. Eur J Clin Microbiol Infect Dis 1991; 10:759.",
"     </a>",
"    </li>",
"    <li>",
"     Rabodonirina, M, Paulus, S, Thevenet, F, et al. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis 1994l; 19:138.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/109\">",
"      Bouza E, Mu&ntilde;oz P, Vega L, et al. Clinical resolution of Scedosporium prolificans fungemia associated with reversal of neutropenia following administration of granulocyte colony-stimulating factor. Clin Infect Dis 1996; 23:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41640/abstract/110\">",
"      Spielberger RT, Tegtmeier BR, O'Donnell MR, Ito JI. Fatal Scedosporium prolificans (S. inflatum) fungemia following allogeneic bone marrow transplantation: report of a case in the United States. Clin Infect Dis 1995; 21:1067.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2424 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41640=[""].join("\n");
var outline_f40_42_41640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYCOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Scedosporium apiospermum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Scedosporium prolificans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      S. apiospermum infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Keratitis and endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Skin, soft tissue and bone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      S. prolificans infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Respiratory tract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Keratitis and endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Central nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Skin, soft tissue and bone infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Disseminated infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2424\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2424|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/36/37440\" title=\"picture 1\">",
"      Scedosporium cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/30/4577\" title=\"picture 2\">",
"      Scedosporium apiospermum microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/53/9043\" title=\"picture 3\">",
"      Pseudallescheria boydii microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/11/28849\" title=\"picture 4\">",
"      S prolificans microsopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36249?source=related_link\">",
"      Diagnosis and treatment of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41641="Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis";
var content_f40_42_41641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Raoul Poupon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/42/41641/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/42/41641/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis (PBC) is characterized by a T-lymphocyte-mediated attack on small intralobular bile ducts (",
"    <a class=\"graphic graphic_picture graphicRef54128 graphicRef66904 \" href=\"mobipreview.htm?32/43/33466\">",
"     picture 1A-B",
"    </a>",
"    ). A continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance (",
"    <a class=\"graphic graphic_picture graphicRef79032 \" href=\"mobipreview.htm?42/7/43127\">",
"     picture 2",
"    </a>",
"    ). The sustained loss of intralobular bile ducts causes the signs and symptoms of cholestasis and eventually results in cirrhosis and liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5737?source=see_link\">",
"     \"Pathogenesis of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signs and symptoms of PBC differ from those of most other liver diseases; thus, the diagnosis may be strongly suspected based upon the clinical findings. As an example, pruritus, hyperpigmentation of the skin, and hepatomegaly in a woman with a cholestatic pattern of liver function tests are common in PBC but unusual in other liver disorders such as acute and chronic hepatitis and alcoholic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A general overview of the clinical manifestations of and diagnostic approach to PBC will be discussed here. Some of the findings (including pruritus, bone disease, and lipid abnormalities and atherosclerosis) are discussed in detail on separate topic reviews. The treatment of this disorder is also presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic is also discussed in a 2009 guideline issued by the American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/5\">",
"     5",
"    </a>",
"    ]. The AASLD guidelines can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     file://www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other types of liver disease, 95 percent of patients with PBC are women. PBC is unique among the autoimmune diseases in that it rarely occurs in childhood or before age 30. The onset is usually between the ages of 30 to 65, but the disease has been reported in women as young as 15 and as old as 93 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. PBC is more common in Caucasian women, but can be seen in other ethnic groups. One study found that disease severity at presentation was higher in non-Caucasians for reasons that were unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of PBC in a well-defined population (Rochester, Minnesota) was estimated to be 2.7 per 100,000 person years (4.5 and 0.7 per 100,000 person years for women and men, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/8\">",
"     8",
"    </a>",
"    ]. The age and gender-adjusted prevalence per 100,000 persons was 65.4 for women and 12.1 for men.",
"   </p>",
"   <p>",
"    The disease burden from PBC appears to be increasing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study from the United Kingdom, the incidence rose from 23 cases per million in 1987 to 32 cases per million in 1994 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study from Victoria, Australia published in 2004 showed that the prevalence was 51 cases per million population, which is significantly higher than the rate found in 1991 (19 cases per million population) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study from Canada estimated that the overall",
"      <span class=\"nowrap\">",
"       age/sex",
"      </span>",
"      adjusted annual incidence was 30.3 cases per million (48.4 and 10.4 per million in women and men, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/11\">",
"       11",
"      </a>",
"      ]. While the incidence had not changed between 1996 and 2002, the prevalence increased from 100 to 227 per million.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is possible that the increase in disease burden is due to better detection and increased awareness rather than a true change in disease incidence. On the other hand, clustering of disease in certain geographical areas has implicated environmental exposures in its pathogenesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5737?source=see_link\">",
"     \"Pathogenesis of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AT PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue and pruritus used to be the most common presenting symptoms of PBC (",
"    <a class=\"graphic graphic_table graphicRef50201 \" href=\"mobipreview.htm?24/9/24731\">",
"     table 1",
"    </a>",
"    ). However, now that the disease is more widely recognized and diagnosed at its earlier stages, approximately 50 to 60 percent of patients are asymptomatic at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In series published in the 1970s, for example, up to 78 percent of patients had fatigue at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. More recent reports have found that, in newly diagnosed patients, approximately one-half complain of fatigue and one-third pruritus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547440121\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many patients with PBC have preserved quality of life, fatigue may be a major factor that can impair quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. Fatigue is associated with excessive daytime somnolence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/20\">",
"     20",
"    </a>",
"    ]. It may have several contributing causes, although it does not appear to be explained by depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. One report suggested that fatigue remains fairly constant over time in individual patients and that it may be associated with decreased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/23\">",
"     23",
"    </a>",
"    ]. Another report found that fatigue correlated with muscle mitochondrial dysfunction manifested as excessive acidosis after exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/24\">",
"     24",
"    </a>",
"    ]. An association with autonomic dysfunction has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal treatment remains uncertain, although observational data have suggested a benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    (a drug approved for treatment of narcolepsy), possibly because of its favorable effects on daytime somnolence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=see_link\">",
"     \"Overview of the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pruritus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pruritus may occur initially during pregnancy and be mistaken for the pruritus of pregnancy. However, the latter disorder resolves in the postpartum period, whereas that due to PBC typically persists. Itching is worse at night, under constricting, coarse garments, in association with dry skin, and in hot, humid weather.",
"   </p>",
"   <p>",
"    Pruritus is often not recognized as a sign of cholestasis and many patients are initially referred to dermatologists. The cause of the pruritus in primary biliary cirrhosis is unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dermatologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 to 50 percent of newly diagnosed patients have hyperpigmentation of skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/26\">",
"     26",
"    </a>",
"    ]. This change is due to melanin deposition, not jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The cause is unknown but similar findings occur in other types of chronic liver disease such as hemochromatosis. Xanthomas are much less common now than were found in patients reported more than 50 years ago when PBC was first recognized as a distinct clinical entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/27,29\">",
"     27,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other skin conditions that appeared to be more common in PBC compared with controls included pruritus (70 versus 22 percent), xerosis (70 versus 2 percent), dermatographism (57 versus 4 percent), and fungal infections of the feet or nails [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/26\">",
"     26",
"    </a>",
"    ]. A dermatologic complaint led to the diagnosis of PBC in almost 40 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rheumatic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal complaints, frequently due to an inflammatory arthropathy, occur in approximately 40 percent of patients with PBC (with some estimates as high as 70 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic rheumatoid arthritis develops in 5 to 10 percent of patients, while the \"arthritis of PBC\" is observed in another 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. The latter disorder is characterized by a transient nondeforming rheumatoid-factor negative synovitis involving one or more peripheral joints [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/31\">",
"       31",
"      </a>",
"      ]. These manifestations are similar to those of hypercholesterolemic arthropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 40 to 65 percent of patients have symptoms of Sj&ouml;gren's syndrome, including keratoconjunctivitis (dry eyes)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      xerostomia (dry mouth) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/34\">",
"       34",
"      </a>",
"      ]. These clinical features usually precede those directly associated with PBC. On the other hand, PBC is an uncommon development in patients with primary Sj&ouml;gren's syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Approximately 5 to 15 percent of patients have limited cutaneous scleroderma, which is frequently associated with anticentromere antibodies and may include the CREST syndrome (Calcinosis cutis Raynaud phenomenon Esophageal dysmotility Sclerodactyly Telangiectasia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/30,36\">",
"       30,36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"       \"Classification of scleroderma disorders\"",
"      </a>",
"      .) In approximately one-half of these individuals, the symptoms of scleroderma occur prior to those of PBC. Clonal expansion of T cells bearing a specific beta chain variable region (TCRBV3) has been demonstrated in some of these patients, suggesting that patients with PBC and CREST syndrome may have a distinct disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unexplained right-upper-quadrant discomfort occurred in 8 percent of patients in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/37\">",
"     37",
"    </a>",
"    ] and has been present in approximately 15 percent of the 1200 patients whom I have seen with this disorder. Rarely, patients present with advanced disease that is manifested by hemorrhage from esophageal varices, ascites, or hepatic encephalopathy.",
"   </p>",
"   <p>",
"    Patients with PBC are at risk for two different types of bone disease: osteoporosis, which is the characteristic bone disorder in PBC and may reflect the inhibitory effect of a retained toxin on the osteoblast; and osteomalacia, which occurs in a small number of patients who are bedridden and have little to no exposure to sunlight. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cognitive impairment (with memory and concentration) has been reported in patients with PBC. In one study, these features were present in 53 percent of 198 patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/38\">",
"     38",
"    </a>",
"    ]. They correlated with the presence of structural brain lesions and autonomic dysfunction but did not correlate with the severity of liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on physical examination vary widely and depend upon the stage of the disease at time of presentation. As an example, the physical examination is often normal in the asymptomatic patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for the patient with hyperpigmentation, the skin may initially be normal but excoriations from scratching due to pruritus may be severe enough to cause bleeding and may occur as the disease progresses. Jaundice is a later manifestation of the disease but may be seen at presentation in some patients. Xanthomas from hyperlipidemia are also late manifestations that occur in less than 5 percent of patients. Xanthelasmas are more common and occur in approximately 10 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=see_link\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hepatosplenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Striking hepatic enlargement is often found, occasionally in asymptomatic patients. Hepatomegaly becomes more common as the disease progresses and is eventually found in approximately 70 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/16\">",
"     16",
"    </a>",
"    ]. The frequency with which splenomegaly is present on initial presentation has not been well described. However, it appears to be decreasing, probably because PBC is currently diagnosed in earlier stages. In my experience with more than 1200 patients, fewer than 5 percent of patients seen since 1990 have had splenomegaly at presentation. Splenomegaly becomes more common as PBC progresses and usually is a sign of portal hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spider nevi, temporal and proximal limb muscle wasting, ascites, and edema are all late manifestations of disease and imply cirrhosis. Kayser-Fleischer rings are a very rare manifestation and result from copper retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum alkaline phosphatase concentration is almost always elevated in PBC, often to striking levels, and is of hepatic origin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .) The value tends to reach a plateau early in the course of the disease and then usually fluctuates within 20 percent of this value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/40\">",
"     40",
"    </a>",
"    ]. Serum levels of 5'-nucleotidase and gammaglutamyl transpeptidase parallel those of alkaline phosphatase.",
"   </p>",
"   <p>",
"    The serum levels of aminotransferases may be normal or slightly elevated, rarely increased more than fivefold above normal. They tend to fluctuate within a relatively narrow range, and are of no prognostic importance unless they are 10 times normal or higher. If so, the overlap syndrome (PBC plus autoimmune chronic hepatitis) should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum bilirubin concentration is usually normal early in the course of the disease but becomes elevated in most patients as the disease progresses. Both the direct and indirect fractions are increased. An elevated serum bilirubin is a poor prognostic sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased numbers of eosinophils have been demonstrated in the blood and liver of patients with PBC, particularly in its early stages, suggesting that they may have a pathogenic role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Antimitochondrial antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimitochondrial antibodies are the serologic hallmark of PBC. They are present in about 95 percent of patients with PBC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5737?source=see_link\">",
"     \"Pathogenesis of primary biliary cirrhosis\"",
"    </a>",
"    .) Thus, an antimitochondrial antibody test should be performed whenever the presence of PBC is suspected. Most assays are 95 percent sensitive and 98 percent specific for PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/44\">",
"     44",
"    </a>",
"    ]. An exception is tests using indirect immunofluorescence, which are operator dependent and have been associated with false-positive and false-negative results.",
"   </p>",
"   <p>",
"    One study suggested that the presence of antimitochondrial antibodies alone was a predictor of the eventual development of PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/45\">",
"     45",
"    </a>",
"    ]. The study focused on 29 patients who had antimitochondrial antibodies but were asymptomatic and had normal liver function. Liver biopsy revealed mild changes that were nondiagnostic but consistent with very early PBC in 24 of 29. At 10 years, symptoms of PBC were present in 76 percent and laboratory signs of cholestasis in 83 percent. Repeat liver biopsy was performed in 10 of the patients. The disease had progressed from stage I to II in two patients and from stage I to III in two. There was no histologic progression in six patients.",
"   </p>",
"   <p>",
"    Approximately 13 percent of first-degree relatives of patients with PBC have antimitochondrial antibodies, suggesting they are susceptible to developing PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/46\">",
"     46",
"    </a>",
"    ]. Whether the early detection of such individuals has a clinical benefit remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antinuclear antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antinuclear antibodies (ANA) are found in up to 70 percent of patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/47-52\">",
"     47-52",
"    </a>",
"    ]. A variety of staining patterns may be present. In one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/50\">",
"     50",
"    </a>",
"    ], the most common staining patterns were nuclear body, nuclear pore complex and homogeneous (19.9, 18.9, and 15.2 percent, respectively) followed by centromere, speckled, Cajal body, and other (12.6, 11.4, 3.7, 4.9 percent respectively).",
"   </p>",
"   <p>",
"    Antinuclear antibodies have clinical significance in PBC for two reasons. First, their presence can cause confusion with autoimmune hepatitis or autoimmune",
"    <span class=\"nowrap\">",
"     hepatitis/PBC",
"    </span>",
"    overlap. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Second, some suggest that ANA may be associated with more rapid progression of disease and a poorer prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/50,53-55\">",
"     50,53-55",
"    </a>",
"    ]. However, the strength of this association and the implications for management are uncertain. For example, PBC patients who are AMA negative and have a positive ANA, a disease often called autoimmune cholangitis but more appropriately AMA negative PBC, have the same outcomes as those who are AMA positive and ANA negative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=see_link\">",
"     \"Definition and treatment of variants of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum lipids may be strikingly elevated in PBC. Serum cholesterol levels are elevated in at least 50 percent of patients, and may exceed 1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in patients with xanthomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients with early primary biliary cirrhosis have mild elevations of low-density and very-low-density lipoproteins (LDL and VLDL) and striking elevations of high-density lipoproteins (HDL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/57\">",
"     57",
"    </a>",
"    ]. This may explain why patients with PBC, despite striking hypercholesterolemia, are not at increased risk of death from atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=see_link\">",
"     \"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other biochemical abnormalities in PBC include increased serum concentrations of IgM, ceruloplasmin, bile acids (which are strikingly elevated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/58\">",
"     58",
"    </a>",
"    ], and hyaluronate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/59\">",
"     59",
"    </a>",
"    ]. Rising hyaluronate levels correlate with the serum bilirubin and histologic worsening of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of PBC has improved markedly during the past two decades. Many patients with early-stage PBC may have a normal life expectancy with treatment. Studies of patients treated with UDCA have suggested a good prognosis in patients initially diagnosed with mild disease who achieve a biochemical response to UDCA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=see_link\">",
"     \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that patients with PBC who are asymptomatic at diagnosis may have a better prognosis than those who have symptoms (such as fatigue), but the strength of this association is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/12,14,60-63\">",
"     12,14,60-63",
"    </a>",
"    ]. Other studies have suggested that patients who have coexisting disorders related to PBC such as thyroiditis, sicca syndrome, and scleroderma also have a worse prognosis even if they do not have the symptoms more classically related to PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible that the better prognosis reported in asymptomatic patients in some studies reflects lead-time bias (ie, that such patients were detected earlier in the course of their disease). Symptoms develop in two to four years in the majority of asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/12\">",
"     12",
"    </a>",
"    ], although about one-third may remain symptom-free for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/61\">",
"     61",
"    </a>",
"    ]. There is no reliable way to predict which patients will develop symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Histologic stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;PBC is classified histologically into four stages. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link\">",
"     \"Histologic scoring systems for chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the natural history of PBC involves histologic progression along these stages, although treatment with UDCA may slow disease progression. In a study involving 916 biopsy specimens from 222 patients followed in the pre-UDCA era, cirrhosis developed within four years in 31 and 50 percent who presented initially with stage I or II disease, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of cirrhosis (stage IV), is associated with a worse prognosis and identifies a group of patients at risk for development of complications related to cirrhosis including variceal bleeding and development of hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In a study of 256 patients seen in the pre-UDCA era, 31 percent developed esophageal varices during a median of 5.6 years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/67\">",
"     67",
"    </a>",
"    ]. One- and three-year survival rates were 83 and 59 percent, respectively, after the development of varices. In another study, the presence of ductopenia on a baseline liver biopsy predicted histologic progression despite UDCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Risk of hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PBC are at increased risk for hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/66,67,69-71\">",
"     66,67,69-71",
"    </a>",
"    ]. A meta-analysis of 17 studies found that patients with PBC had a higher risk of HCC compared with the general population (relative risk 19; 95% CI 11-27) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest individual studies included a total of 725 patients who were followed for an average of nine years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/71\">",
"     71",
"    </a>",
"    ]. The incidence of HCC during follow-up was approximately 0.36 per 100 patient-years. Overall, about 3 percent of patients developed HCC during the nine-year observation period. On multivariable analysis, the only independent risk factor was advanced histologic stage. In addition, male sex was a risk factor in a subset analysis; male sex was also a risk factor in an earlier study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146187727\">",
"    <span class=\"h2\">",
"     Antimitochondrial antibody-negative PBC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with antimitochondrial antibody (AMA)-negative PBC are thought to have a similar clinical course and response to treatment as patients with AMA-positive PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Antimitochondrial antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antinuclear antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the presence of antinuclear antibodies (in particular anticentromere antibodies) may identify a subgroup of patients at increased risk for progressing to liver failure. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Antinuclear antibodies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between PBC and cigarette smoking has been suggested in epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/75\">",
"     75",
"    </a>",
"    ]. At least two studies also suggested that cigarette smoking is associated with more advanced fibrosis stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. In one of the studies, never-smokers were significantly less likely to have advanced fibrosis (METAVIR fibrosis score of 3 or 4) than patients who had smoked in the past or were current smokers (16 versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/77\">",
"     77",
"    </a>",
"    ]. For each pack-year increase in smoking, there was a 5 percent increase in the likelihood of advanced fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link&amp;anchor=H4#H4\">",
"     \"Histologic scoring systems for chronic liver disease\", section on 'Metavir score'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Natural history models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several predictive models based upon laboratory and clinical data have been proposed. The best validated is the Mayo survival model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/41\">",
"     41",
"    </a>",
"    ]. The Mayo model is used widely in studies of PBC to provide an assessment of the expected rate of survival free of liver transplantation. Its role in predicting survival in individual patients is less clear.",
"   </p>",
"   <p>",
"    It is based upon five independent variables including age, the total serum bilirubin, albumin, prothrombin time, and the severity of fluid retention. Of these, the serum bilirubin concentration is the most heavily weighted. An original model was developed to predict seven-year survival while an updated model has been developed to predict two-year survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/41,78\">",
"     41,78",
"    </a>",
"    ]. As noted above, survival in patients who respond to UDCA appears to be improved compared with that predicted by the Mayo model and thus the accuracy of the model in predicting prognosis in patients on UDCA has not been fully established. A full description of the model and a calculator are provided on the internet (",
"    <a class=\"external\" href=\"file://www.mayoclinic.org/gi-rst/models.html\">",
"     file://www.mayoclinic.org/gi-rst/models.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Genetic variations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain polymorphisms of genes involved in immunity (CTLA-4 and TNF-alpha) were associated with prognosis and response to UDCA therapy in a study of 258 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/79\">",
"     79",
"    </a>",
"    ]. More studies are needed to understand the relevance of these observations to natural history models or the choice of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A guideline issued by the American Association for the Study of Liver Diseases suggests that PBC should be considered in patients with an elevated serum alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/5\">",
"     5",
"    </a>",
"    ]. After excluding other causes of liver disease (including alcohol and drugs), patients should undergo a cross-sectional imaging test of the liver to exclude biliary obstruction. Serum should be tested for antimitochondrial, antinuclear and anti-smooth muscle antibodies. A liver biopsy should be considered, especially if the serum aspartate aminotransferase is &gt;5x normal or AMA is negative. The AASLD recommendations conclude that the diagnosis is established when two of the following three criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biochemical evidence of cholestasis based mainly on alkaline phosphatase elevation",
"     </li>",
"     <li>",
"      Presence of AMA",
"     </li>",
"     <li>",
"      Histologic evidence of nonsuppurative destructive cholangitis and destruction of interlobular bile ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of PBC should particularly be considered in women with unexplained itching, fatigue, jaundice, or unexplained weight loss with right-upper-quadrant discomfort,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    whose serum alkaline phosphatase is unaccountably elevated. Such patients should be questioned about symptoms of diseases frequently associated with PBC, such as Sj&ouml;gren's syndrome (dry eyes and mouth), arthritis, and Raynaud phenomenon. Sicca symptoms are particularly common, being present in many as one-half of patients with PBC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should also be questioned about the use of medications, some of which may cause cholestasis similar to that of primary biliary cirrhosis. Among the most common drugs that cause cholestasis are phenothiazines, synthetic androgenic steroids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"     tolbutamide",
"    </a>",
"    , and in our experience,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Primary biliary cirrhosis is probably present if the serum alkaline phosphatase and IgM concentrations are both elevated and the antimitochondrial antibody test is positive, titer 1:80 or higher. Modest elevations of the aminotransferases and hypercholesterolemia provide corroborative data. The serum albumin concentration and prothrombin time are typically normal at time of diagnosis. There are striking elevations of serum bile acids but they are rarely measured in routine practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally perform a percutaneous liver biopsy to confirm the diagnosis and provide information about the stage of the disease and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/81\">",
"     81",
"    </a>",
"    ]. Exceptions are patients who are older than 75 (or have a short life expectancy due to comorbidities) or those with contraindications to liver biopsy. However, not all centers perform a liver biopsy.",
"   </p>",
"   <p>",
"    The pathognomonic florid bile duct lesion is uncommonly seen in percutaneous needle biopsies of the liver (",
"    <a class=\"graphic graphic_picture graphicRef54128 graphicRef66904 graphicRef53861 \" href=\"mobipreview.htm?41/33/42522\">",
"     picture 1A-C",
"    </a>",
"    ). However, the greater the number of portal triads in the specimen, the more likely it is that these lesions and granulomas will be present. The continuous assault on the bile duct epithelial cells leads to their gradual destruction and eventual disappearance. The hepatocyte injury is associated with foamy degeneration which is thought to be due to the toxic effect of retained bile acids (",
"    <a class=\"graphic graphic_picture graphicRef65727 \" href=\"mobipreview.htm?5/1/5143\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Histologic findings in PBC are often staged on a scale of zero to four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/42/41641/abstract/82\">",
"     82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage zero &mdash; normal liver",
"     </li>",
"     <li>",
"      Stage one &mdash; inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal connective tissue confined to the portal areas",
"     </li>",
"     <li>",
"      Stage two &mdash; inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrosis confined to portal and periportal areas",
"     </li>",
"     <li>",
"      Stage three &mdash; bridging fibrosis",
"     </li>",
"     <li>",
"      Stage four &mdash; cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the history, physical findings, blood tests, and liver biopsy findings are consistent, imaging tests or cholangiography are not needed. Endoscopic retrograde cholangiography is typically normal or shows narrow caliber bile ducts in PBC and is helpful in the patient in whom the antimitochondrial antibody test is negative and the possibility of primary sclerosing cholangitis or a carcinoma of the bile duct or pancreas exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/34/2594?source=see_link\">",
"       \"Patient information: Primary biliary cirrhosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms of PBC are fatigue and pruritus, although approximately one-half of patients are asymptomatic when diagnosed (",
"    <a class=\"graphic graphic_table graphicRef50201 \" href=\"mobipreview.htm?24/9/24731\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis should be considered in the patient, particularly a woman, who complains of unexplained itching, fatigue, jaundice, or unexplained weight loss with right-upper-quadrant discomfort,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      whose serum alkaline phosphatase is unaccountably elevated. Such patients should be questioned about symptoms of diseases frequently associated with PBC, such as Sj&ouml;gren's syndrome (dry eyes and mouth), arthritis, and Raynaud phenomenon. Sicca symptoms are particularly common, being present in many as one-half of patients with PBC. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should also be questioned about the use of medications, some of which may cause cholestasis similar to that of primary biliary cirrhosis. Among the most common drugs that cause cholestasis are phenothiazines, synthetic androgenic steroids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/49/42774?source=see_link\">",
"       tolbutamide",
"      </a>",
"      , and in our experience,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis is probably present if the serum alkaline phosphatase and IgM concentrations are both elevated and the antimitochondrial antibody test is positive. Modest elevations of the aminotransferases and hypercholesterolemia provide corroborative data. We suggest the diagnosis of PBC be confirmed by percutaneous liver biopsy, which will also provide information about the stage of the disease and prognosis. Poor prognostic factors are elevated serum bilirubin, low serum albumin, and significant interface hepatitis at the time of diagnosis and poor response to ursodiol after six months of treatment with it.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22246986\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/1\">",
"      Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/2\">",
"      Ludwig J. New concepts in biliary cirrhosis. Semin Liver Dis 1987; 7:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/3\">",
"      Moebius U, Manns M, Hess G, et al. T cell receptor gene rearrangements of T lymphocytes infiltrating the liver in chronic active hepatitis B and primary biliary cirrhosis (PBC): oligoclonality of PBC-derived T cell clones. Eur J Immunol 1990; 20:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/4\">",
"      Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/5\">",
"      Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology 2009; 50:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/6\">",
"      Dahlan Y, Smith L, Simmonds D, et al. Pediatric-onset primary biliary cirrhosis. Gastroenterology 2003; 125:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/7\">",
"      Peters MG, Di Bisceglie AM, Kowdley KV, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology 2007; 46:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/8\">",
"      Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/9\">",
"      James OF, Bhopal R, Howel D, et al. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology 1999; 30:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/10\">",
"      Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: high prevalence in migrant populations. Gastroenterology 2004; 127:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/11\">",
"      Myers RP, Shaheen AA, Fong A, et al. Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. Hepatology 2009; 50:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/12\">",
"      Balasubramaniam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990; 98:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/13\">",
"      Tornay AS Jr. Primary biliary cirrhosis: natural history. Am J Gastroenterol 1980; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/14\">",
"      Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/15\">",
"      Sherlock S, Scheuer PJ. The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 1973; 289:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/16\">",
"      Long RG, Scheuer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977; 72:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/17\">",
"      Selmi C, Gershwin ME, Lindor KD, et al. Quality of life and everyday activities in patients with primary biliary cirrhosis. Hepatology 2007; 46:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/18\">",
"      Poupon RE, Chr&eacute;tien Y, Chazouill&egrave;res O, et al. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004; 40:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/19\">",
"      Newton JL, Bhala N, Burt J, Jones DE. Characterisation of the associations and impact of symptoms in primary biliary cirrhosis using a disease specific quality of life measure. J Hepatol 2006; 44:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/20\">",
"      Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/21\">",
"      van Os E, van den Broek WW, Mulder PG, et al. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/22\">",
"      Al-Harthy N, Kumagi T, Coltescu C, Hirschfield GM. The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice. Hepatology 2010; 52:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/23\">",
"      Jones DE, Bhala N, Burt J, et al. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut 2006; 55:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/24\">",
"      Hollingsworth KG, Newton JL, Taylor R, et al. Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin Gastroenterol Hepatol 2008; 6:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/25\">",
"      Newton JL, Davidson A, Kerr S, et al. Autonomic dysfunction in primary biliary cirrhosis correlates with fatigue severity. Eur J Gastroenterol Hepatol 2007; 19:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/26\">",
"      Koulentaki M, Ioannidou D, Stefanidou M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006; 101:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/27\">",
"      AHRENS EH Jr, PAYNE MA, KUNKEL HG, et al. Primary biliary cirrhosis. Medicine (Baltimore) 1950; 29:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/28\">",
"      Mills PR, Skerrow CJ, MacKie RM. Melanin pigmentation of the skin in primary biliary cirrhosis. J Cutan Pathol 1981; 8:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/29\">",
"      MacMAHON HE, THANNHAUSER SJ. Xanthomatous biliary cirrhosis; a clinical syndrome. Ann Intern Med 1949; 30:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/30\">",
"      Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004; 97:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/31\">",
"      Culp KS, Fleming CR, Duffy J, et al. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982; 57:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/32\">",
"      Caramella C, Avouac J, Sogni P, et al. Association between rheumatoid arthritis and primary biliary cirrhosis. Joint Bone Spine 2007; 74:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/33\">",
"      Mills PR, Rooney PJ, Watkinson G, MacSween RN. Hypercholesterolaemic arthropathy in primary biliary cirrhosis. Ann Rheum Dis 1979; 38:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/34\">",
"      Liu B, Zhang FC, Zhang ZL, et al. Interstitial lung disease and Sj&ouml;gren's syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 2008; 27:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/35\">",
"      Hatzis GS, Fragoulis GE, Karatzaferis A, et al. Prevalence and longterm course of primary biliary cirrhosis in primary Sj&ouml;gren's syndrome. J Rheumatol 2008; 35:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/36\">",
"      Mayo MJ, Jenkins RN, Combes B, Lipsky PE. Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. Hepatology 1999; 29:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/37\">",
"      Laurin JM, DeSotel CK, Jorgensen RA, et al. The natural history of abdominal pain associated with primary biliary cirrhosis. Am J Gastroenterol 1994; 89:1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/38\">",
"      Newton JL, Hollingsworth KG, Taylor R, et al. Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008; 48:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/39\">",
"      Fleming CR, Dickson ER, Hollenhorst RW, et al. Pigmented corneal rings in a patient with primary biliary cirrhosis. Gastroenterology 1975; 69:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/40\">",
"      Christensen E, Crowe J, Doniach D, et al. Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 1980; 78:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/41\">",
"      Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/42\">",
"      Yamazaki K, Nakadate I, Suzuki K, et al. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol 1996; 91:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/43\">",
"      Terasaki S, Nakanuma Y, Yamazaki M, Unoura M. Eosinophilic infiltration of the liver in primary biliary cirrhosis: a morphological study. Hepatology 1993; 17:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/44\">",
"      Muratori L, Granito A, Muratori P, et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/45\">",
"      Metcalf JV, Mitchison HC, Palmer JM, et al. Natural history of early primary biliary cirrhosis. Lancet 1996; 348:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/46\">",
"      Lazaridis KN, Juran BD, Boe GM, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007; 46:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/47\">",
"      Marasini B, Gagetta M, Rossi V, Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001; 60:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/48\">",
"      Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003; 98:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/49\">",
"      Joshi S, Cauch-Dudek K, Wanless IR, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 2002; 35:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/50\">",
"      Yang WH, Yu JH, Nakajima A, et al. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? Clin Gastroenterol Hepatol 2004; 2:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/51\">",
"      Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/52\">",
"      Nakamura M, Shimizu-Yoshida Y, Takii Y, et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 2005; 42:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/53\">",
"      Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005; 54:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/54\">",
"      Poupon R, Chazouilleres O, Corpechot C, Chr&eacute;tien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/55\">",
"      Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007; 45:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/56\">",
"      Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/57\">",
"      Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/58\">",
"      Poupon RE, Ouguerram K, Chr&eacute;tien Y, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 1993; 17:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/59\">",
"      Poupon RE, Balkau B, Gu&eacute;chot J, Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994; 19:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/60\">",
"      Prince M, Chetwynd A, Newman W, et al. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002; 123:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/61\">",
"      Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/62\">",
"      Springer J, Cauch-Dudek K, O'Rourke K, et al. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999; 94:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/63\">",
"      Jones DE, Al-Rifai A, Frith J, et al. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up. J Hepatol 2010; 53:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/64\">",
"      Locke GR 3rd, Therneau TM, Ludwig J, et al. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/65\">",
"      Nijhawan PK, Therneau TM, Dickson ER, et al. Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology 1999; 29:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/66\">",
"      Jones DE, Metcalf JV, Collier JD, et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. Hepatology 1997; 26:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/67\">",
"      Gores GJ, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989; 96:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/68\">",
"      Kumagi T, Guindi M, Fischer SE, et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/69\">",
"      Suzuki A, Lymp J, Donlinger J, et al. Clinical predictors for hepatocellular carcinoma in patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/70\">",
"      Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/71\">",
"      Cavazza A, Caballer&iacute;a L, Floreani A, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/72\">",
"      Liang Y, Yang Z, Zhong R. Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis. Hepatology 2012; 56:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/73\">",
"      Mendes F, Lindor KD. Antimitochondrial antibody-negative primary biliary cirrhosis. Gastroenterol Clin North Am 2008; 37:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/74\">",
"      Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997; 25:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/75\">",
"      Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005; 42:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/76\">",
"      Zein CO, Beatty K, Post AB, et al. Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: A cross validated retrospective assessment. Hepatology 2006; 44:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/77\">",
"      Corpechot C, Gaouar F, Chr&eacute;tien Y, et al. Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2012; 56:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/78\">",
"      Murtaugh PA, Dickson ER, Van Dam GM, et al. Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. Hepatology 1994; 20:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/79\">",
"      Poupon R, Ping C, Chr&eacute;tien Y, et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol 2008; 49:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/80\">",
"      Tsianos EV, Hoofnagle JH, Fox PC, et al. Sj&ouml;gren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990; 11:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/81\">",
"      Scheuer PJ. Ludwig Symposium on biliary disorders--part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 1998; 73:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/42/41641/abstract/82\">",
"      Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3621 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41641=[""].join("\n");
var outline_f40_42_41641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS AT PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H547440121\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pruritus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dermatologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rheumatic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hepatosplenomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Antimitochondrial antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Histologic stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Risk of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146187727\">",
"      Antimitochondrial antibody-negative PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Natural history models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Genetic variations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22246986\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3621\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3621|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/48/12040\" title=\"picture 1A\">",
"      Primary biliary cirrhosis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/16/27911\" title=\"picture 1B\">",
"      Primary biliary cirrhosis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/5/3159\" title=\"picture 1C\">",
"      Florid bile duct lesion PBC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/7/43127\" title=\"picture 2\">",
"      Primary biliary cirrhosis VIII - high power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/1/5143\" title=\"picture 3\">",
"      Foamy degeneration in PBC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3621|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/9/24731\" title=\"table 1\">",
"      Manifestations of PBC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35911?source=related_link\">",
"      Definition and treatment of variants of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18149?source=related_link\">",
"      Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/19/34105?source=related_link\">",
"      Overview of the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/38/5737?source=related_link\">",
"      Pathogenesis of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/34/2594?source=related_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_42_41642="Adenosarcoma";
var content_f40_42_41642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70818%7EOBGYN%2F50860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70818%7EOBGYN%2F50860&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine adensosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Mann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Uterine adenosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This cellular stroma of this tumor forms hypercelluar cuffs surrounding the benign-appearing, mostly slit-like glands. Foci of squamous metaplasia are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41642=[""].join("\n");
var outline_f40_42_41642=null;
var title_f40_42_41643="Lung preservation procurement";
var content_f40_42_41643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Donor lung preservation during procurement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ventilation",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Tidal volume: 8 to 10 mL per kg",
"        </p>",
"        <p>",
"         FIO2: 50 percent",
"        </p>",
"        <p>",
"         PEEP: 5 cm H2O",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Anticoagulation (once lungs and heart exposed)",
"        </strong>",
"       </td>",
"       <td>",
"        Heparin 250 to 300 units per kg, intravenously",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Prostaglandin pretreatment",
"        </strong>",
"       </td>",
"       <td>",
"        Prostaglandin E1 (PGE1, Alprostadil) 500 mcg via main pulmonary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Flush solution",
"        </strong>",
"       </td>",
"       <td>",
"        Low potassium dextran (Perfadex&reg;)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Temperature",
"        </strong>",
"       </td>",
"       <td>",
"        4 to 8&deg;C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Antegrade flush",
"        </strong>",
"       </td>",
"       <td>",
"        Infuse 50 to 75 mL/kg of flush solution into main pulmonary artery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cardioplegia solution (only when heart is used for transplantation)",
"        </strong>",
"       </td>",
"       <td>",
"        Infuse retrograde from aorta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Topical cooling",
"        </strong>",
"       </td>",
"       <td>",
"        Iced saline slush added to pleural and pericardial spaces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Retrograde flush, after removal of heart",
"        </strong>",
"       </td>",
"       <td>",
"        Infuse 250 mL of flush solution into each pulmonary vein orifice and vent at pulmonary artery opening",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41643=[""].join("\n");
var outline_f40_42_41643=null;
var title_f40_42_41644="Four hr Vanco desens";
var content_f40_42_41644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59149&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid vancomycin desensitization protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Premedication:",
"        </strong>",
"        Diphenhydramine 50 mg IV and hydrocortisone 100 mg IV 15 minutes prior to initiation of protocol, then every six hours throughout protocol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Infusion no.",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dilution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vancomycin dose (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Concentration (mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"       <td>",
"        0.0002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1:10",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        standard",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        1. Prepare a standard bag of 500 mg vancomycin in 250 mL NS or D5W; label as infusion number 5, vancomycin 2 mg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        2. Draw up 10 mL of the standard vancomycin 2 mg/mL preparation and place in 100 mL bag of NS or D5W; label as infusion number 4, vancomycin 0.2 mg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        3. Draw up 10 mL of the 0.2 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 3, vancomycin 0.02 mg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        4. Draw up 10 mL of the 0.02 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 2, vancomycin 0.002 mg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        5. Draw up 10 mL of the 0.002 mg/mL solution and place in a 100 mL bag of NS or D5W; label as infusion number 1, vancomycin 0.0002 mg/mL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Infusion rate directions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Initiate infusion rate at 0.5 mL/minute (30 mL/hour) and increase by 0.5 mL/min (30 mL/hour) as tolerated every 5 minutes to a maximum rate of 5 mL/minute (300 mL/hour). If pruritus, hypotension, rash, or difficulty breathing occurs, stop infusion and reinfuse the previously tolerated infusion at the highest tolerated rate. This step may be repeated up to three times for any given concentration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upon completion of infusion number 5, immediately administer the required dose of vancomycin in the usual dilution of NS or D5W over 2 hours. Decrease rate if patient becomes symptomatic or, alternatively, increase rate if patient tolerated dose. Administer diphenhydramine 50 mg orally 60 minutes prior to each dose.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     D5W: dextrose 5 percent in water; NS: sodium chloride 0.9 percent solution.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wazny LD, et al. Desensitization protocols for vancomycin hypersensitivity. The Annals of Pharmacotherapy 2001; 35:1458. Copyright &copy; 2001 Harvey Whitney.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41644=[""].join("\n");
var outline_f40_42_41644=null;
var title_f40_42_41645="Contents: Drug eruptions";
var content_f40_42_41645=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Drug eruptions",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Drug eruptions",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/6/9322\">",
"           Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/60/42951\">",
"           Acute generalized exanthematous pustulosis (AGEP)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/63/35834\">",
"           Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/57/43929\">",
"           Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/50/24360\">",
"           Exanthematous (morbilliform) drug eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/50/9000\">",
"           Fixed drug eruption",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/48/3848\">",
"           Lichenoid drug eruption (drug-induced lichen planus)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-E41937BAB1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_42_41645=[""].join("\n");
var outline_f40_42_41645=null;
var title_f40_42_41646="Frykman I radius fracture lateral view";
var content_f40_42_41646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frykman I radius fracture lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On the lateral x-ray of the same fracture, the dorsal angulation of the distal fragment is apparent. Such fractures are often referred to by the eponym Colles'. Note this is not a true lateral: the images of the radius and ulna are not superimposed, and the pisiform (black arrow) is seen dorsal to the distal pole of the scaphoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Erik L Schroeder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41646=[""].join("\n");
var outline_f40_42_41646=null;
var title_f40_42_41647="Ear relaps polychondritis";
var content_f40_42_41647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F54829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F54829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ear involvement in relapsing polychondritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normal (contralateral) ear in a patient with relapsing polychondritis.",
"    <br>",
"     (B) The affected ear in the same patient.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of John H Stone, MD, MPH.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_42_41647=[""].join("\n");
var outline_f40_42_41647=null;
